Suppressors Of Cytokine Signaling in G-CSF-induced neutrophil development by Geijn, G.J.M. (Gert-Jan) van de
Suppressors Of Cytokine Signaling in 
G-CSF-induced neutrophil development
Gert-Jan van de Geijn
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 1
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 2
Suppressors Of Cytokine Signaling (SOCS) in 
G-CSF-induced neutrophil development
Suppressors Of Cytokine Signaling (SOCS) in
G-CSF-geïnduceerde ontwikkeling van neutrofiele granulocyten
Proefschrift
Ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam
op gezag van de Rector Magnificus Prof. dr. S. W. J. Lamberts
en volgens het besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op
donderdag 24 juni 2004 om 13.30 uur
door
Gerardus Johannes Maria van de Geijn
geboren te Nijmegen
Chapter1v1macv2.qxd  07-05-2004  00:50  Page 3
Promotiecommissie
Promotoren: Prof. dr. I.P. Touw
Prof. dr. B. Löwenberg
Overige leden: Prof. dr. J. A. Grootegoed
Dr. J.N.J. Philipsen
Dr. P. Coffer
The work described in this thesis was performed at the Institute of Hematology, Erasmus
Medical Center Rotterdam, The Netherlands. This work was supported by the Dutch
Cancer Society “Koningin Wilhemina Fonds”. Financial support from the Dutch Cancer
Society (KWF) for printing of this thesis is gratefully acknowledged.
Cover by Karola van Rooyen and Gert-Jan van de Geijn
Printed by [Optima] Grafische Communicatie, Rotterdam
Chapter1v1macv2.qxd  07-05-2004  00:52  Page 4
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 5
Contents
Chapter 1 Introduction
1.1) Hematopoiesis
1.2) Hematopoietic growth factors
1.3) G-CSF
1.4) G-CSF receptor
1.5) Signaling pathways coupled to the G-CSF receptor
1.6) Negative regulation of G-CSF signaling
1.7) G-CSF receptor defects in myeloid disorders
Partly published in:
Granulocyte colony-stimulating factor and its receptor in 
normal hematopoietic cell development and myeloid
disease
Reviews of Physiology, Biochemistry and Pharmacology, 
2003; 149:53-71 
Chapter 2 Signaling mechanisms coupled to tyrosines in the 
granulocyte colony-stimulating factor receptor orchestrate
G-CSF-induced expansion of myeloid progenitor cells
Blood, 2003; 101(7):2584-2590.
Chapter 3 Distinct activities of suppressor of cytokine signaling 
(SOCS) proteins and involvement of the SOCS box in 
controlling G-CSF signaling
J. Leukocyte Biology, in press
Chapter 4 G-CSF receptor truncations found in SCN/AML relieve 
SOCS3-controlled inhibition of STAT5 but leave 
suppression of STAT3 intact
Blood, in press
9
11
11
12
13
15
20
23
37
59
77
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 6
Chapter 5 General discussion
5.1) G-CSF signaling
5.2) SHP-2 versus SOCS3 mediated inhibition via G-CSF-
receptor-Y729
5.3) Contribution of SOCS1 to lineage choice?
5.4) Differential effects of SOCS inhibition on G-CSF-induced STAT
activation revealed by mutation of critical domains in the G-CSF
receptor
5.5) G-CSF receptor internalization and SOCS-mediated inhibition
5.6) Current model of aberrant signaling of G-CSF-R-d715
5.7) Concluding remarks 
Summary
Samenvatting
List of abbreviations
Beste allemaal
Curriculum Vitae
101
102
103
104
106
107
108
110
115
120
123
124
127
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 7
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 8
CHAPTER 1
Introduction
partly published in
Granulocyte colony-stimulating factor and its receptor in normal
hematopoietic cell development and myeloid disease
Van De Geijn GJ, Aarts LH, Erkeland SJ, Prasher JM, Touw IP
Reviews of Physiology, Biochemistry and Pharmacology, 2003; 149:53-71 
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Hematopoiesis
The formation of blood cells, hematopoiesis, is a tightly regulated, yet flexible,
process that ensures appropriate levels of the different blood cell types. In
addition, during stress situations such as bleeding or infection, blood cell
development rapidly adapts to accomodate the extra demand for cells of specific
subtypes. All blood cells are derived from the pluripotent hematopoietic stem cell
(HSC), which gives rise to multipotent progenitor cells. The progenitor cell
compartiment has a vast proliferative potential that ensures generation of
sufficient blood cells out of relatively few and rarely dividing HSCs. Multipotent
progenitor cells differentiate into committed progenitors that ultimately give rise
to each of the different blood cell lineages: red blood cells, platelets,
lymphocytes, macrophages, dendritic cells, natural killer cells and granulocytes.
Granulocytes are essential for a good functioning first line of defence against
infections. Granulocytes contain cytoplasmic granules and are classified based
on cell morphology and staining of the granules as eosinophilic, basophilic or
neutrophilic granulocytes. The latter, also known as neutrophils, are the most
common type of granulocytes, and take care of phagocytosis and destruction of
invading microorganisms, using amongst others myeloperoxidase, acid
hydrolases, collagenase, elastase, lactoferrin and lysozyme, present in their
granules. Neutrophils have a life span limited to approximately 4-5 days. They
are either destroyed during defensive action or become senescent and die (1). An
average adult human produces an estimated 50 million neutrophils per minute,
which can be increased drastically during infection (2). This process is, like all
hematopoiesis, controlled by signals provided by the stromal environment in the
bone marrow and by cytokines and hematopoietic growth factors (HGF).
Hematopoietic growth factors
The cloning and functional characterization of hematopoietic growth factors
(HGF) and their cell surface receptors represent milestones in understanding the
molecular control of blood cell development (3-9). In addition, these
developments have had a profound impact on clinical hematology, most notably
through the introduction of HGF-based therapies. HGFs are produced by stromal
and endothelial cells, fibroblasts, monocytes and macrophages and specialized
cells in organs such as the kidney and the liver. The range of action of HGFs
Introduction
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Chapter 1
varies considerably. So called early-acting HGFs act only on pluripotent
progenitors whereas late-acting factors stimulate proliferation and terminal
differentiation of more committed cells. Moreover, some HGFs are restricted to
a specific lineage while others are active throughout the hematopoietic system.
The most important HGF that drives formation of neutrophils is granulocyte
colony-stimulating factor (G-CSF).
G-CSF 
G-CSF is a member of the cytokine class I superfamily, structurally characterized
by four antiparallel α-helices (10). G-CSF supports proliferation, survival and
differentiation of neutrophilic progenitor cells in vitro and provides
nonredundant signals for maintenance of steady-state neutrophil levels in vivo
(11-15). Typically, G-CSF-deficient (gcsf-/-) or G-CSF-receptor-deficient (gcsfr
-/-) mice manifest a selective neutropenia, with blood neutrophil levels at 15-
30% of those in wild type (WT) littermates. The number of myeloid progenitor
cells in the bone marrow of these mice is also significantly decreased (14-16).
Experiments with G-CSF- or G-CSF-R-deficient mice infected with Listeria
monocytogenes have established that G-CSF signaling is also required for
"reactive" or "emergency" granulopoiesis in response to bacterial infections (15,
17). In addition, G-CSF enhances neutrophil effector functions, such as
superoxide anion generation, release of arachidonic acid and production of
leukocyte alkaline phosphatase and myeloperoxidase by mature neutrophils (18-20). 
The clinical application of G-CSF has been particularly beneficial in treatment of
various forms of neutropenia. For example, this is the case for severe congenital
neutropenia (SCN), a disease characterized by a myeloid maturation arrest in the
bone marrow leading to a drastic reduction in the peripheral neutrophil level and
susceptibility to opportunistic bacterial infections that can be fatal. G-CSF
treatment ameliorates the neutropenia and associated infections in a large
majority of cases (21-23). Recently, G-CSF-treatment has been shown to
improve the response to chemotherapy of standard-risk AML patients (24).
Another major and initially unexpected benefit of G-CSF is its ability to induce
the release of hematopoietic stem and progenitor cells from the bone marrow into
the peripheral blood. This has resulted in utilization of G-CSF in the mobilization
and isolation of peripheral hematopoietic stem cells for transplantation purposes
(25). The mechanism by which G-CSF mobilizes these cells into the periphery is
12
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not fully understood but is thought to involve multiple effector pathways,
including proteolytic enzyme release, activation of chemokine receptors, and
modulation of adhesion molecules (26, 27). G-CSF also induces mobilization of
neutrophils from the bone marrow, probably via similar mechanisms (28).
G-CSF receptor
The G-CSF receptor (G-CSF-R) is a member of the now well-characterized
hematopoietin receptor superfamily (29, 30). This family is structurally
characterized by four highly conserved cysteine residues and a tryptophan-serine
repeat (WSXWS) in the extracellular domain. Both motifs are located within the
so-called cytokine receptor homology (CRH) region. Murine and human G-CSF-
receptors are single transmembrane proteins of 812 and 813 amino acid residues
respectively, with 62.5% homology at the amino acid level (31). The extracellular
domain of the G-CSF-R contains 603 amino acid residues and includes an
immunoglobulin-like module, the CRH domain, and three fibronectin type III
(FNIII) modules (Figure 1A). 
Introduction
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Figure 1: G-CSF receptor structure and ligand binding. A) The extracellular domain of
the G-CSF receptor consists of an immunoglobin (Ig)-like domain, the cytokine receptor
homology (CRH) domain with its N- and C-terminal barrel (BN and BC), containing four
cysteine residues and a WSXWS motif, and three fibronectin type III (FNIII) modules. The
cytoplasmic region contains three boxes that are conserved in some members of the
hematopoietin receptor superfamily and four tyrosine residues. B) Upon ligand binding, G-
CSF and the G-CSF-R form a 2:2 tetrameric complex. G-CSF binds with its type II binding
motif to the CRH domain and with its type III motif to the Ig-like domain.
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The CRH domain is composed of two "barrel-like" modules, each formed by
seven β strands. Similar to the CRH domains of gp130, the growth hormone
(GH) receptor, and the erythropoietin receptor (Epo-R), these barrels are
connected by a proline-rich linker that positions them at an approximately
perpendicular angle (32). Crystallography studies of receptor/ligand
complexes, epitope mapping with monoclonal antibodies and alanine scanning
mutagenesis have provided detailed insight into the composition of these
complexes and the contact sites involved in ligand recognition. These data
suggest that G-CSF and the G-CSF-R form a 2:2 tetrameric complex (33)
(Figure 1B). Although it was initially proposed that this involved "pseudo-
symmetric" binding of G-CSF to two sites within the CRH domain of the G-
CSF-R, it now appears more likely that G-CSF binds to one site within the
CRH domain, via its type II binding motif, and to one site within the Ig-like
domain, via type III motif binding (34). This configuration is similar to that
found in the IL-6/gp130 complex (32). 
The role of the FNIII domains in G-CSF-R function is not clear. Interestingly, the
second FNIII module of the G-CSF-R confers ligand-independent activation to a
chimeric G-CSF-R/gp130 receptor in Cos cells (35). Although this suggests that
the FNIII domain may be involved in the formation of an active receptor
complex, the significance of this mechanism for G-CSF-R activation under more
physiological conditions remains to be established.
The intracellular domain of the G-CSF-R has limited sequence homology to
other hematopoietin receptor superfamily members. However, it does possess
two motifs in the membrane-proximal region, called box 1 and box 2, which
are also found in the Epo-R, gp130, and in the β chains of the IL-2 and IL-3
receptors (36, 37). This membrane-proximal region is essential for the
transduction of proliferation signals (38). The C-terminal (membrane-distal)
region of the G-CSF-R contains a third conserved motif (box 3) that is shared
only with gp130 (39, 40). This region has been implicated in the control of G-
CSF-induced differentiation of myeloid progenitor cell lines and more
recently also in the transduction of phagocytic signals in mature neutrophils
(41-43). Importantly, as will be discussed later, mutations have been reported
in severe congenital neutropenia (SCN) patients that result in the truncation of
this C-terminal region. The cytoplasmic domain of human G-CSF-R further
contains four conserved tyrosine residues, at positions 704, 729, 744 and 764
14
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(equivalent to 703, 728, 743 and 763 in the murine G-CSF-R), which function
as docking sites for multiple SH2-containing signaling proteins.
G-CSF-R expression has been demonstrated on a variety of hematopoietic cells,
including myeloid progenitors, mature neutrophils, monocytes, myeloid and
lymphoid leukemia cells and normal B and T lymphocytes (44-53). G-CSF-R
expression has also been detected in nonhematopoietic tissues, for instance at the
materno-fetal interface and on vascular endothelial cells and in a wide variety of
fetal organ tissues (54-56). The G-CSF-R probably plays minimal or redundant
roles in embryonic development, since newborn G-CSF-R deficient mice are
normal, without any detectable abnormalities other than severe neutropenia (14,
16). In addition to the WT form of the G-CSF-R, at least 6 isoforms have been
described, all of which are products of alternative mRNA splicing. The
expression levels of these isoforms in bone marrow progenitor cells are low or
undetectable compared to the WT G-CSF-R, suggesting that their physiological
role in normal myelopoiesis is minimal. However, overexpression of certain
isoforms has been reported in cases of acute myeloid leukemia that result in
disturbed G-CSF responses in leukemic progenitor cells (7, 31, 57).
Signaling pathways coupled to the G-CSF receptor
In the past decade, the basic principles of hematopoietin receptor signaling have
been elucidated. The canonical JAK/STAT pathways are generally seen as the
pivotal signaling mechanisms of these receptors. Indeed, studies in mouse
knockout models have established specific as well as more general roles for
JAKs and STATs in cellular responses to growth factors and cytokines (58-60).
The JAK/STAT signaling components activated by G-CSF-R are JAK1, JAK2,
Tyk2, STAT1, STAT3, and STAT5 (61-65). 
As is the case for most other hematopoietin receptors, the p21Ras and
phosphatidylinositol 3-kinase (PI-3K)/protein kinase B (PKB) signaling
Introduction
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The role of the G-CSF-R tyrosines has been evaluated in different myeloid cell
line models but their contributions to G-CSF-induced colony formation and the
clonogenic capacity of primary bone marrow progenitors remains unclear. In
Chapter 2 of this thesis these questions are addressed and both the collective and
individual roles of the G-CSF-R tyrosines were studied.
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pathways are activated by the G-CSF-R, and both pathways were found to
contribute to G-CSF-induced survival and proliferation (Figure 2)(16, 66-69).
Studies in the chicken B cell system DT40 suggested that activation of PI-3K
depends on the presence of p55Lyn. This pathway is thought to involve
association of Lyn with c-Cbl, and subsequent docking of the p85 subunit of PI-
3K to Y731 of Cbl (70-73). 
JAK/STAT pathways
Although it has been firmly established that G-CSF activates JAK1, JAK2 and
Tyk2, the specific roles of these kinases in G-CSF signaling are not clear (61-63).
By employing a JAK-deficient human fibrosarcoma cell model, Shimoda et al.
showed that JAK1, but not the other activated JAK-family members, is critical
for receptor phosphorylation and STAT activation (63). In contrast, co-expression
of dominant negative forms of either JAK1, JAK2 or Tyk2 with a WT G-CSF-R
in Cos cells completely blocked G-CSF-induced STAT5 activation in these cells
(67). Moreover, JAK1-deficient mice possess normal numbers of neutrophils,
which would also argue against a major and non-redundant role of JAK1 in
granulopoiesis (74). Clearly, studies in appropriate hematopoietic cell models,
16
Figure 2: Signaling mechanisms activated by the WT G-CSF receptor. Schematic
representation of the intracellular domain of the G-CSF receptor upon ligand binding. The
tyrosines of the receptor become phosphorylated and function as docking sites for
signaling molecules. In addition, several signaling routes are activated independent of
G-CSF-R tyrosines.
SHC
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lacking each of the JAK family members activated by the G-CSF-R, are needed
to resolve this issue. 
Among the different STAT family members, STAT1 is only weakly and
transiently activated by G-CSF and studies in STAT1-deficient mice suggest that
it is redundant for granulopoiesis (75-77). In contrast, STAT3 is robustly
activated by the G-CSF-R. Y704 and Y744 of the G-CSF-R are major docking
sites for STAT3 (Figure 2). At low ligand concentrations, STAT3 activation
depends largely on the availability of at least one of these sites (65, 69, 75, 78).
In contrast, investigations in Ba/F3 cells, and more recently in primary bone
marrow cultures, have established that at saturating G-CSF concentrations
STAT3 can also be activated via a tyrosine-independent route. The latter
mechanism requires the presence of the membrane-distal region of the G-CSF-R
(79, 80). Although the exact nature of this tyrosine independent route is still
unclear, this observation has led to the idea that different mechanisms for STAT3
activation might be involved in the control of steady-state granulopoiesis at a low
G-CSF level (mainly tyrosine-dependent) versus "emergency" granulopoiesis
initiated by an increased level of G-CSF (tyrosine-independent) (79).
The question of how STAT3 contributes to G-CSF-controlled granulopoiesis has
been addressed quite extensively in both in vitro and in vivo models. Introduction
of dominant negative (DN) forms of STAT3, which either prevent dimerization
or DNA binding of STAT3 complexes, in myeloid cell lines resulted in a lack of
growth arrest and a block in neutrophilic differentiation (81, 82). Importantly,
following forced G1 arrest, cells expressing DN-STAT3 fully regained their
ability to differentiate, suggesting that STAT3 is required for cell cycle exit, a
prerequisite for myeloid differentiation, but not for execution of the
differentiation program itself (82, 83). Studies in conditional knockout mice with
selective deletion of STAT3 in hematopoietic progenitor cells showed that
production of functional neutrophils in vivo does not require STAT3, thereby
confirming the in vitro findings that STAT3 is not essential for neutrophil
differentiation per se. In fact, these conditional STAT3 knockout mice developed
a neutrophilia which was driven by a hyperproliferative response of bone marrow
progenitors to G-CSF (84). 
McLemore et al. suggested that STAT3 is not only critical for G-CSF-induced
growth arrest and differentiation, but also for proliferation of myeloid
Introduction
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progenitors, which appears partly in conflict with the data obtained in the
conditional STAT3 knockout and in the cell line models (85). They based this
conclusion on a mouse model expressing a  truncated G-CSF-R, in which the
remaining STAT3 binding site (Y704) is mutated (d715F). The d715F mice
demonstrated a complete loss of STAT3 activation in response to G-CSF and
were severely neutropenic. G-CSF-driven proliferation of myeloid progenitors
from d715F mice in colony cultures was almost completely restored by
introduction of a constitutively active form of STAT3 (STAT3C). This suggests
that STAT3 activation via Y704 plays a major role in proliferative responses. A
possible explanation for the phenotypic differences between STAT3-/- and
d715F mice is that in the latter model G-CSF signaling is aberrant in more ways
than in just its inability to activate STAT3. For instance, internalization of the
truncated receptors is severely hampered and signaling abilities and signal
duration are quite drastically altered compared to the WT G-CSF-R (see
below)(86). Additionally, the constitutively active STAT3 protein is an
oncoprotein that may perturb multiple signaling mechanisms and thus synergize
with G-CSF in evoking proliferative responses (87). The combination of the
truncated G-CSF-R with the constitutively active STAT3 in the study by
McLemore et al. might therefore overestimate the role of STAT3 in normal
granulopoiesis.
The mechanisms by which STAT3 contributes to cell cycle exit in myeloid
progenitor cells remain unclear. The cyclin-dependent kinase (cdk) inhibitor
p27Kip1 has been proposed to play a role in this process (82). G-CSF induces
expression of p27Kip1 in 32D cells. Dominant-negative forms of STAT3
completely block this G-CSF-induced p27Kip1 expression. Furthermore, a
putative STAT3 binding site was identified in the promoter region of p27Kip1 that
was functional in both electrophoretic mobility shift assays and in luciferase
reporter assays. Finally, myeloid progenitors from p27Kip1-deficient mice showed
significantly increased proliferation and reduced differentiation in response to G-
CSF, compared with wild-type controls. Taken together, these findings suggested
that STAT3 controls cell cycle arrest of myeloid cells, at least partly, via
transcriptional upregulation of p27Kip1. It is important to note however that
transcription of p27Kip1 is also, and arguably more robustly, induced by
transcription factors of the Forkhead family, which are negatively controlled by
phosphorylation through the PI-3K/PKB pathway (88, 89). Interestingly, recent
studies in HepG2 cells indicate that one of these factors, FKHR, acts as a
18
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coactivator of STAT3 in IL-6 induced transcriptional activity (90). Whether this
also applies to G-CSF-induced upregulation of p27Kip1 remains to be addressed. 
STAT5 activation is mediated by the membrane proximal region of the G-CSF-
R, independent of tyrosine residues (91). Although the exact mechanism of
activation is still unknown, this may involve direct recruitment to JAK kinases
(92) (Figure 2). STAT5 has been implicated in proliferation and survival signals
provided by the G-CSF-R (91). The role of STAT5 in steady-state granulopoiesis
appears limited, as double-knockout mice lacking both the STAT5A and STAT5B
isoforms have only moderately reduced numbers of CFU-G and no overt
neutropenia (93). Whether STAT5 is involved in G-CSF-driven emergency
granulopoiesis has not been established. Irrespective of its role in nonmalignant
granulopoiesis, STAT5 may be a crucial player in the pathogenesis of myeloid
malignancies. For instance, the transforming abilities of the Tel-JAK2 fusion
protein, a hallmark of a specific subset of myeloid leukemia, depend entirely on
the presence of STAT5 (94). 
SHP-2
Generation of different mouse models demonstrated that SH2 domain-containing
phosphatase 2 (SHP-2) is important for the formation of myeloid, erythroid and
lymphoid cells (95-98). SHP-2 has 2 SH2 domains and a C-terminal phosphatase
domain, and needs recruitment to a phosphotyrosine for its activation (99).
Despite its apparently crucial role in development of multiple blood cell lineages,
the mechanisms of SHP-2 action are poorly understood. SHP-2 has multiple
functions, it is able to dephosphorylate STAT5, interacts with JAKs and is also
required for efficient activation of the p21 Ras to ERK MAP kinase pathway in
response to a number of stimuli (95, 100-106). The mechanisms of SHP-2
recruitment to the G-CSF-R are not clear yet. Whereas Ward et al. reported
binding of Y704 and Y764 to the SH2 domains of SHP-2, using Far Western
technology, others were unable to detect the latter interaction (69, 107). 
Introduction
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The role of SHP-2 in G-CSF-R signaling is still not understood. In the
experiments in Chapter 4 we investigated which region of the G-CSF-R is
required for SHP-2 recruitment and for the formation of a SHP-2-STAT5
complex that may be involved in downregulation of G-CSF-induced STAT5
activity.
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p21Ras/MAP kinase pathways
Y764 of the G-CSF-R plays a major role in proliferation signaling in cell line
models as well as in primary myeloid progenitor cells (66, 80). Once
phosphorylated, Y764 forms a binding site for the SH2 domains of SHC and
GRB2, signaling intermediates of the p21Ras pathway (66, 69, 108, 109). GRB2
can also be recruited via docking to SHC (110-113). Loss of Y764 results in a
significant reduction of p21Ras activation, and accelerated neutrophil
differentiation (66, 109, 114). Interestingly, SCN-derived G-CSF-R truncation
mutants that lack the receptor C-terminus gain the ability of p21Ras activation by
an alternative mechanism, probably involving Y704 of the G-CSF-R (66, 69). 
A well-known signaling cascade downstream of p21Ras signaling is the Raf-
MEK-ERK Mitogen-activated protein kinase (MAP kinase) signaling pathway.
MAP kinase pathways are activated upon phosphorylation by MAP kinase-
kinases in a cascade like manner in response to stimuli such as growth factors,
cytokines or in response to cellular stress. Activation can, depending on the
cellular context and stimulus, result in induction of proliferation, differentiation
or apoptosis. In addition to ERK, a number of other MAP kinases have been
identified, of which p38 and JNK are best characterized to date. A number of
studies showed that the ERK MAP kinase cascade is the major effector pathway
downstream from p21Ras responsible for proliferative signaling in cell lines as
well as in primary myeloid progenitor cells (80, 114-120). Activation of other
MAP kinases downstream of p21Ras, i.e., the p38MAP kinase and Jun N-
terminal kinase (JNK) is also controlled mainly via Y764, but the role of these
kinases in G-CSF signaling is still unclear (107, 109, 117). 
Negative regulation of G-CSF signaling
The inhibition of cytokine responses is governed by multiple mechanisms
including dephosphorylation of signaling molecules by phosphatases, receptor
endocytosis, and proteasomal targeting. Mechanisms that have been implicated
in downregulation of G-CSF signaling are discussed below. 
SHP-1
The role of the SH2 domain-containing protein tyrosine phosphatase SHP-1 as a
negative regulator of granulopoiesis has been established utilizing so-called
"moth-eaten" (mev) mice (121, 122), which possess a mutation in the SHP-1 gene
20
Chapter1v1macv2.qxd  05-05-2004  21:46  Page 20
resulting in reduced phosphatase activity (123). These mice exhibit aberrant
regulation in several myeloid and lymphoid lineages, including substantial
increases in the number of immature granulocytes (124-126). SHP-1 protein
levels are increased in a post-transcriptional manner during G-CSF-induced
differentiation of 32D cells. Ectopic overexpression of SHP-1 in these cells
inhibited proliferation and stimulated differentiation, whereas introduction of a
phosphatase-dead SHP-1 mutant gave the opposite result (127). In contrast to the
Epo-R or the GM-CSF/IL-3/IL-5-R common β chains, G-CSF-R tyrosines do not
serve as docking sites for the SH2 domain of SHP-1, suggesting that intermediate
signaling molecules may be involved in the recruitment of SHP-1 into the G-
CSF-R complex (126-128).
SHIP
A 145 kDa phosphorylated protein was detected following G-CSF stimulation in
both Shc and in GRB2 immunoprecipitations. The formation of these complexes
depended on the presence of Y764 of the G-CSF-R (108). This protein was later
identified as the SH2-containing inositol phosphatase (SHIP) protein (68).
Studies in SHIP-deficient mice showed that this phosphatase is important for
modulating hematopoietic signaling, particularly in the myeloid lineage.
SHIP -/- mice die early, most likely due to the extensive infiltration of myeloid
cells observed in the lungs. The numbers of neutrophils and monocytes in these
mice are increased, which is due to an elevated number of myeloid progenitors
in the bone marrow (129). Furthermore, survival of neutrophils lacking SHIP is
prolonged following apoptosis-inducing stimuli or growth factor withdrawal.
Finally, PI(3,4,5)P3 accumulation and PKB activation are both increased and
prolonged in SHIP-/- cells. Taken together these data suggest a role for SHIP as
a negative regulator of growth factor-mediated PI-3K/PKB activation and
survival of myeloid cells (130).
SOCS proteins
Suppressor of cytokine signaling (SOCS) proteins are important mediators of
negative feedback in response to many cytokines. To date, the SOCS protein
family contains 8 known members: SOCS1-7 and CIS. All SOCS proteins
contain an SH2-domain and a C-terminal conserved domain called the SOCS
box; for a review, see (131). SOCS1 and SOCS3 have two extra conserved
domains in common; the extended SH2 subdomain (ESS) and the kinase
inhibitory region (KIR) (132-134). Different SOCS proteins use different
Introduction
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mechanisms for inhibition of signaling (Figure 3). They can compete with
positively acting signaling substrates for receptor tyrosine docking, as was
demonstrated for inhibition of GH-induced STAT5 signaling by CIS (135). The
second mechanism is only used by SOCS1 and SOCS3: they utilize their ESS
and SH2 domains for recruitment to activated JAK kinases. Subsequently, the
KIR acts as a pseudosubstrate and inhibits kinase activity (132, 133, 136).
SOCS1 directly binds to JAK kinases (132, 133, 137, 138) whereas SOCS3
requires recruitment to phosphotyrosines in activated receptors for efficient
signal inhibition (139-142). The third mechanism of inhibition of signaling by
SOCS proteins involves the C-terminal SOCS box. Elongins B and C bind the
SOCS box and although the exact composition of the resulting protein complex
is still unclear, it is postulated to have E3 ubiquitin ligase activity (143-145). This
may contribute to ubiquitination and subsequent proteasomal degradation of
signaling molecules (143-146). In addition, the SOCS box also regulates the
stability of SOCS proteins themselves. However, the exact role of elongin
binding to the SOCS box remains to be elucidated since there are conflicting
reports on whether the SOCS box contributes to SOCS protein stability or
degradation (143, 144, 147-149).
Expression of SOCS proteins is under the direct transcriptional control of STATs
(137, 150-152). It is thus conceivable that SOCS proteins are also involved in
downmodulation of G-CSF signaling as a direct consequence of activation of
STAT5 and the robust and sustained activation of STAT3 by G-CSF. Among the
different SOCS family members reported to be upregulated by G-CSF, SOCS3 is
most prominently induced (153, 154). G-CSF-induced SOCS3 expression is
severely reduced in STAT3-/- mice, indeed suggesting that SOCS3 is the major
STAT3 target responsible for inhibition of G-CSF signaling (84). SOCS3-
deficient mice demonstrated a prominent role for SOCS3 in regulating placental
development and signaling by leukemia inhibiting factor (LIF) (155-157). 
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Which members of the SOCS protein family inhibit G-CSF-induced activation
of STAT3, STAT5 and G-CSF-induced colony formation by primary myeloid
progenitors is unknown. In addition, which SOCS proteins are expressed during
G-CSF-induced neutrophilic differentiation is unclear. The role of the SOCS box
in inhibition of G-CSF-R signaling has not been established as well. These
questions are addressed in Chapter 3 of this thesis.
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G-CSF receptor defects in myeloid disorders
A number of mutations or rare polymorphisms in the GCSFR gene have been
reported in myeloid disorders and these were found to perturb signaling functions
of the receptor. Mutations, rarely found in myelodysplasia (MDS) and de novo
AML, occur most frequently in SCN (but not in cyclic or idiopathic neutropenia).
Elucidation of the functional consequences of these abnormalities has
contributed to our understanding of the role of specific domains of the G-CSF-R
in signaling. 
Specific mutations in the GCSFR gene have thus far not been reported in MDS
and AML without a history of SCN. On the other hand, Awaya et al. found an
increased occurrence of a novel splice variant of G-CSF-R with an alteration in
the juxtamembrane region of the receptor (158). Via an as yet unknown
mechanism, this variant conferred increased proliferative signals in response to
G-CSF compared to the wild type G-CSF-R. However, because this receptor
variant is also found at low frequencies (2%) in normal bone marrow cells and is
Introduction
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Figure 3: Different mechanisms of SOCS-mediated inhibition of JAK-STAT
signaling. Members of the SOCS protein family utilize different mechanisms to inhibit
signaling of cytokine receptors as shown in this schematic representation. CIS competes
with STATs for recruitment to phosphorylated tyrosine residues in cytokine receptors.
SOCS1 and SOCS3 are capable to inhibit JAK kinase activity using their kinase inhibitory
region (KIR). SOCS1 is recruited directly to activated JAK whereas SOCS3 has a lower
affinity for direct interaction with JAK and therefore is recruited via phosphorylated
tyrosines in cytokine receptors. The third mechanism involved targeting of signaling
molecules for proteasomal degradation, which is mediated through the C-terminal
conserved SOCS box.
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still only detectable in less than 8% of the myeloid progenitor cells in MDS, its
role in the pathogenesis of MDS remains uncertain.
In de novo AML, activating mutations in receptor tyrosine kinases FLT3 and c-
kit occur in more than 25% of cases and have a significant impact on disease
prognosis (159-163). In contrast, mutations in hematopoietin receptors, including
G-CSF-R, have only very rarely been detected. A mutation leading to
overexpression of a nonfunctional splice variant of G-CSF-R was reported in 1
out of 70 cases analyzed (57). This variant receptor has the alternative C-terminal
34 amino acids of the class IV G-CSF-R (alternatively known as D-7), linked to
amino acid 682, which is just C-terminal of box-2. It thus lacks most of the
functional domains, including all the tyrosine based docking motifs, which
explains why it lacks most of its signaling abilities. Although this case so far
appears to be unique, altered ratios of Class I(WT)/Class IV G-CSF-R levels
have been reported in more than 50% of AML samples, which could be
suggestive of a more general role for abnormal G-CSF-R function in AML (164).
Significantly, even at relatively low levels of expression, the Class IV variant was
reported to interfere with differentiation induction mediated via the WT G-CSF-
R in 32Dcl3 cells (165). 
In an SCN patient who failed to respond to G-CSF treatment, a mutation in the
extracellular domain of the G-CSF-R mutation was found that changed a
conserved proline residue in the "hinge" motif located between the NH2- and
COOH-terminal barrels of the CRH domain resulting (166). This was proposed
to prevent the formation of 2:2 ligand/receptor complexes. Contrary to the C-
terminal truncations, this mutant receptor showed drastically reduced activation
of STAT5 and was severely hampered in proliferation and cell survival signaling
in 32D cells, while differentiation-inducing properties were retained.
The most frequent mutations found in SCN are nonsense mutations in a critical
glutamine-rich stretch, which result in C-terminal truncation of the G-CSF-R.
Clones harboring such acquired mutations are detected in the neutropenic phase
of the disease in approximately 20% of patients (167, 168). In some cases,
affected myeloid cells arise from minority clones, originally making up only 1 to
2 % of the myeloid progenitor cell compartment. However, clones with G-CSF-
R mutations become overt in more than 80% of the SCN cases upon progression
to MDS and AML, suggesting that G-CSF-R truncations represent a critical step
24
Chapter1v1macv2.qxd  05-05-2004  11:03  Page 24
in the expansion of the (pre-) leukemic clones (169). An important question in
this context is how G-CSF treatment contributes to the outgrowth of the
leukemia. In a recent update from the Severe Chronic Neutropenia International
Registry, evolution of SCN to MDS or AML was reported in 35 of 387 patients
with congenital neutropenia with a cumulative risk of 13% after 8 years of G-
CSF treatment, but there was no apparent relationship to duration or dose of G-
CSF treatment (170). 
The role of these truncation mutations in leukemic transformation has been
analyzed in further detail in mouse models in which the nonsense mutation was
introduced in the GCSFR gene by knock-in strategies (G-CSF-R-d715) (171,
172). Although insufficient to cause leukemia themselves, these mutations were
recently found to cooperate with additional oncogenic hits, such as loss of the
DNA repair protein MSH2, to accelerate tumorigenesis. Interestingly,
preliminary results also suggest an association between loss of MSH2 function
and G-CSF-R mutations in SCN patients at high risk for AML/MDS progression
supporting this murine data (Prasher et al., manuscript in preparation). Mice
expressing the truncated G-CSF-R exhibit hyperproliferation of myeloid
progenitor cells in reponse to G-CSF (171, 172). Multiple signaling abnormali-
ties have been linked with this hyperproliferation, including defective receptor
internalization (173). This is in part due to the loss of a serine type di-leucine
motif in box 3 (amino acids 749-755) and the immediate downstream sequence
stretch of amino acids 756 to 769 (174, 175). Mutation of this di-leucine motif
reduced receptor endocytosis and delayed the attenuation of signaling (174, 175).
Due to lack of the C-terminus in G-CSF-R-d715, negative feedback by SHP-1
and SHIP is lost as well (68, 128). Furthermore, activation of the PI-3K/PKB
pathway is increased and STAT5 activation is drastically prolonged (67, 86).
Although the exact underlying molecular mechanisms remain to be elucidated,
the increased STAT5/STAT3 activation ratio of the G-CSF-R-d715 is implicated
in prolonged survival and proliferation of G-CSF-R-d715 cells (86).
Introduction
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It is possible is that lack of negative feedback by SOCS proteins contributes to
the hyper responsive phenotype of G-CSF-R-d715. Due to the aberrant
activation of STAT3 and STAT5 the induction of SOCS expression by G-CSF-
R-d715 may be altered as well. In addition SOCS proteins may differentially
affect STAT3 and STAT5 activity of G-CSF-R-d715. These issues were
examined as described in Chapter 4 of this thesis.
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Abstract
Granulocyte colony-stimulating factor (G-CSF) is the major regulator of
neutrophil production. Studies in cell lines have established that conserved
tyrosines Y704, Y729, Y744 and Y764 within the cytoplasmic domain of G-CSF
receptor (G-CSF-R) contribute significantly to G-CSF-induced proliferation,
differentiation and cell survival. However, it is unclear whether these tyrosines
are equally important under more physiological conditions. Here, we
investigated how individual G-CSF-R tyrosines affect G-CSF responses of
primary myeloid progenitors. We generated G-CSF-R-deficient mice and
transduced their bone marrow cells with tyrosine "null" mutant (mNull), single
tyrosine "add back" mutants or wild type (WT) receptors. G-CSF-induced
responses were determined in primary colony assays, serial replatings and
suspension cultures. We show that removal of all tyrosines had no major
influence on primary colony growth. However, adding back Y764 strongly
enhanced proliferative responses, which was reverted by inhibition of ERK
activitity. Y729, which we found to be associated with the suppressor of cytokine
signaling SOCS3, had a negative effect on colony formation. After repetitive
replatings, the clonogenic capacities of cells expressing mNull gradually dropped
compared to WT. The presence of Y729, but also Y704 and Y744, both involved
in activation of STAT3, further reduced replating efficiencies. Conversely, Y764
greatly elevated the clonogenic abilities of myeloid progenitors, resulting in a
more than 104-fold increase of colony forming cells over mNull after the fifth
replating. These findings suggest that tyrosines in the cytoplasmic domain of G-
CSF-R, although dispensable for G-CSF-induced colony growth, recruit
signaling mechanisms that regulate the maintenance and outgrowth of myeloid
progenitor cells. 
38
Chapter2v1mac.qxd  03-05-2004  04:13  Page 38
Introduction
Granulocyte colony stimulating factor (G-CSF) supports the proliferation,
survival and differentiation of neutrophilic progenitor cells (1-4). G-CSF
deficient mice manifest a selective neutropenia, with blood neutrophil levels at
30% of those in wild type (WT) mice. Blood neutrophil levels in mice lacking G-
CSF receptors (gcsfr -/-) are also severely reduced, i.e., approximately 15% of
WT littermates (5). In addition, the numbers of myeloid progenitor cells in the
bone marrow of gcsfr -/- mice are significantly decreased (5). These observations
have established that the G-CSF-R provides nonredundant signals for
maintaining steady-state neutrophil levels (5, 6).
The G-CSF-R belongs to the cytokine receptor superfamily and possesses a
single transmembrane region (1). Signaling molecules downstream of the G-
CSF-R include JAK1, JAK2 and Tyk2, the signal transducer and activator of
transcription (STAT) proteins, STAT1, STAT3 and STAT5 (7-13), the Src kinases
p55Lyn and p56/59Hck (14-16), components of the p21Ras/Raf/MAPK pathway
(17-19) and the (SH2) domain-containing protein tyrosine phosphatases SHP-1
and SHP-2 (19-21). The cytoplasmic domain of human G-CSF-R contains four
conserved tyrosine residues, at positions 704, 729, 744 and 764 (equivalent to
703, 728, 743 and 763 in mouse G-CSF-R). Three of these tyrosines are located
in the carboxy terminal region implicated in the control of differentiation (22,
23). Upon receptor activation, these tyrosines are phosphorylated and become
docking sites for multiple SH2-containing signaling proteins, e.g., STAT3 (Y704
and Y744), Shc (Y764) and GRB2 (Y764) (21, 24, 25). 
We previously constructed a series of tyrosine (Y) to phenylalanine (F)
substitution mutants of the G-CSF-R and expressed these in 32D cells to study
their involvement in G-CSF signaling (25-27). These studies demonstrated that
G-CSF-R substitution mutants lacking just one of the four tyrosines were still
fully capable of transmitting differentiation signals in 32D cells (24). Strikingly,
cells expressing mutant Y764F showed significantly accelerated differentiation
with a concomitant reduction in proliferation, suggesting that Y764 plays an
essential role in controlling the balance between proliferation and differentiation.
Recently, similar observations have been made in primary bone marrow cells
transduced with chimeric EGFR/G-CSF-R Y764F (28). G-CSF-R lacking all
tyrosines (mNull) fails to elicit proliferation and differentiation in 32D cells,
G-CSF and expansion of myeloid progenitor cells
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although survival signals are still transduced (25). The presence of Y704 or
Y744, which serve as major docking sites for STAT3, restored G-CSF-induced
proliferation and differentiation to a significant extent (13, 25). Introduction of
Y764, involved in p21Ras activation and signaling via ERK and p38MAPK
pathways (19, 24, 25, 29), generated strong proliferative signals resulting in
exponential growth without neutrophilic differentiation. A specific function and
signaling mechanism linked to Y729 did not emerge from these studies. 
The mechanisms by which G-CSF signaling is negatively regulated have not
been elucidated. In contrast to, for example, the Epo receptor or GM-CSF/IL-
3/IL-5 receptor common β chain, G-CSF-R tyrosines do not serve as docking
sites for the protein tyrosine phosphatase SHP-1, although negative effects of
SHP-1 on G-CSF signaling have been reported (20, 30, 31). Because STAT3 and
STAT5 are prominently activated by G-CSF, it is conceivable that suppressor of
cytokine signaling (SOCS) proteins, which are under the direct transcriptional
control of STATs, are involved in downmodulation of G-CSF responses (32-34).
The SH2 domain of SOCS1 has a high affinity for JAK kinases and interferes
directly with JAK activity (35). On the other hand, other SOCS proteins, such as
SOCS3, are recruited to phosphotyrosines in activated receptors and exert their
negative activity either by blocking positively acting signaling substrates
docking to the same receptor tyrosine, by inhibiting the activity of receptor
associated kinases or by proteosomal targeting of signaling molecules (32-34). 
Although myeloid cell lines have provided useful models for studying G-CSF
signaling, these cells are transformed and immortalized and therefore do not fully
recapitulate the physiological features of normal myeloid progenitor cells. In the
present study, we have employed retroviral transduction of G-CSF-R mutants
into bone marrow cells of G-CSF-R deficient mice to investigate how signals
emanating from the cytoplasmic tyrosine residues in the G-CSF-R contribute to
the clonogenic abilities of primary murine myeloid progenitor cells. We show
that tyrosines are dispensable for G-CSF-induced colony formation per se, but
individually contribute significantly to both G-CSF-induced colony growth and
the maintenance of clonogenicity after sequential replatings. Prominent negative
regulatory effects on colony growth were projected by Y729, which we found to
be associated with recruitment of SOCS3. Conversely, Y764 greatly enhanced
proliferative signals through activation of the ERK kinases. 
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Cells and culture 
Embryonic stem (ES) cells (ES-E14), a gift from M. Hooper, Edinburgh, U.K.,
were cultured as described (36). Briefly, cells were grown in culture medium
consisting of Dulbecco's Modified Eagle's Medium (DMEM, Gibco-BRL, Breda,
The Netherlands), 50% Buffalo rat liver-conditioned medium, 10% fetal calf
serum (FCS, ES-qualified, Gibco-BRL) supplemented with 1% nonessential
amino acids (Gibco-BRL), 0.1 mM 2-mercaptoethanol (Sigma Chemical Co, St.
Louis, MO), 100 U/ml penicillin, 100µg/ml streptomycin (Gibco BRL) and 1000
U/ml leukemia inhibitory factor (LIF; Gibco BRL) in dishes coated with 0.1%
gelatin (Sigma). The cells were passaged every 2 to 3 days.
Targeting construct and probe
The targeting strategy used to inactivate the gcsfr gene is shown in Figure 1.
Isolation, cloning and sequencing of genomic DNA were done according to
standard procedures (37). Genomic DNA was isolated from a mouse
129SV/Cosmid library (Cosmid SC1-6 SuperCos 1, Stratagene cloning systems,
La Jolla, California) as described (38). A region of 10 kb including exon 7 to 17
of the gcsfr gene was replaced by a Neo gene driven by the PGK promoter. To
construct the targeting vector a 2.9 kb Sau3AI - PstI fragment containing exon 5
and 6, and a 4.5 kb XbaI fragment (3-prime of the gcsfr gene, including the non-
coding region of exon 17) were cloned into pBluescript yielding pEUR11 and
pEUR5, respectively. pEUR5 was opened by SpeI, and PGK-Neo was inserted in
reverse orientation, yielding pEUR17. pEUR17 was opened by NotI, blunted, and
subsequently cut by XhoI. The resulting 6.5 kb NotI-XhoI fragment containing
the 4.5 kb XbaI fragment and the PGK-Neo gene was ligated into pEUR11 after
ApaI opening, blunting and subsequent XhoI digestion, resulting in pEUR18. A
unique NotI site in the vector backbone was used for linearization prior to
transfection. A 0.6 kb Sau3A fragment 5-prime of exon 4 (probe A) was used to
screen for homologous recombination, yielding a 9.6 kb band in germ line
configuration, and a 7 kb band after homologous recombination.
G-CSF and expansion of myeloid progenitor cells
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Disruption of the gcsfr-gene by homologous recombination
E14-ES cells (107) were transfected with 25 µg linearized pEUR18 by
electroporation using a Progenetor II, PG200 Hoefer Gene pulser set at 350
V/cm, 1200 µF, 10 msec. The next day, cells were transferred to culture medium
containing 200 µg/ml G418 (Gibco BRL), with G418 resistant colonies picked
on day 8 or 9 after electroporation. Genomic DNA of these colonies was digested
with HindIII, transferred to nylon membranes, and hybridized to probe A and a
neomycin probe. Correctly targeted clones were subjected to cytogenetic analysis
and clones with a normal karyotype were used for blastocyst injections.
Generation of gcsfr-knock out mice
Two ES cell clones were injected into blastocysts of C57BL/6 mice. The
resulting male chimeras were mated to FVB females to generate gcsfr +/- F1
mice. Heterozygous gcsfr +/- mice were intercrossed to obtain gcsfr -/- mice.
DNA was isolated from tail segments and analyzed by PCR using primers for
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Figure 1: Targeting strategy to inactivate the gcsfr gene. A) Targeting strategy to
delete exons 7-16 of the gcsfr gene in ES cells. The position of the probe used to screen
recombinant colonies is shown. Southern analysis of HindIII digests of genomic DNA
detected an 9.6-kb band from the wild type allele and a 7-kb band from the targeted allele
(not shown). B) Specific binding of G-CSF to bone marrow cells from gcsfr +/+, gcsfr +/-,
and gcsfr -/- mice analyzed by flow cytometry. Cells were incubated with biotinylated G-
CSF in the absence (solid line) or presence (dotted line) of a 100-fold molar excess of
nonlabeled G-CSF followed by incubation with PE-conjugated streptavidin.
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exon 17 (5'-GTATATCCCTGTGTTCAGGAAACC and 5'-GGCAGGGTC-
TTCAAGATACAAGG) and primers for the neo gene (5'-TACTCGGATGGAA-
GCCGGTC and 5'-AGTCGATGAATCCAGAAAAG).
Flow cytometric analysis of G-CSF-R expression
Expression levels of G-CSF-R on neutrophilic cells were measured by flow
cytometry. To this end, G-CSF was biotinylated using D-biotinoyl-ε-
aminocaproic acid-N-hydroxysuccinimide ester (Biotin-7-NHS; Boehringer,
Mannheim, Germany). Free biotin was removed by gel-filtration on Sephadex G-
25. Bone marrow cells (106) were incubated in 96-well plates for 60 minutes at
room temperature in 25 µl PBA (phosphate-buffered saline with 1 % BSA and
0.1 % NaN3) and 0.2 µg/ml biotinylated G-CSF, either in the absence or the
presence of a 100-fold molar excess of non-biotinylated G-CSF. Subsequently,
cells were incubated for 30 minutes at 4oC with phycoerythrin-conjugated
streptavidin (SA-PE, Caltag Laboratories, Burlingame, CA). To determine G-
CSF-R expression on transduced bone marrow cells, cells were labeled for 30
min at 4oC with biotinylated anti human G-CSF-R antibody (LMM741,
Pharmingen, San Diego, CA) and subsequently with SA-PE. Cells were
subjected to flow cytometric analysis on a FACScan (Becton-Dickinson,
Sunnyvale, CA). 
Construction of G-CSF-R retroviral vectors and virus production
Vectors containing cDNA encoding human G-CSF-R wild-type (WT) and
tyrosine substitution mutants have been described previously (13). Inserts were
recloned into the retroviral vector pBabe, containing a puromycine resistance
gene. Correct insertion was verified by nucleotide sequencing. Phoenix E virus
producer cells (a gift from G. Nolan, Stanford, CA) were transfected with these
constructs using Promega Profection Mammalian Transfection Systems.
Supernatants containing high-titer, helper-free recombinant viruses were
harvested after culturing approximately 80% confluent producer cells for 16-20
hours in DMEM medium (with 5% FCS and Penicillin/Streptomycin) and passed
through a 45µm filter before use.
Retroviral infection of hematopoietic progenitor cells
Bone marrow cells were harvested from the femurs and tibiae of 8 to 12 week-
old G-CSF-R-deficient mice as described (38). After depletion of adherent cells,
the remaining cells were fractionated on a PercollTM density gradient (Amersham
G-CSF and expansion of myeloid progenitor cells
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Pharmacia Biotech, Uppsala, Sweden) as described (39). Cells were washed
twice in HBSS/5% FCS/0.5% BSA, and prestimulated for 2 days in Cell Gro®
(Boehringer Ingelheim Bioproducts Partnership Heidelberg, Germany)
supplemented with a cytokine cocktail containing mIL-3 (10 ng/ml), hFLT3-
ligand, hTpo, mSCF and GM-CSF (all 100 ng/ml) at a final density of 5x105
cells/ml. Cells where then transferred to 35-mm culture dishes (Becton
Dickinson, Lincoln Park, NJ) coated with 12 µg/ml recombinant fibronectin
44
Figure 2: Expression of G-CSF-R mutants. A) Schematic representation of cytoplasmic
domains of human G-CSF-R wild-type and tyrosine substitution mutants showing
positioning of conserved tyrosines relative to membrane proximal Box1 and Box2. B) Flow
cytometric analysis of G-CSF-R expression on gcsfr -/- bone marrow cells retrovirally
transduced with G-CSF-R WT and tyrosine mutants shown in panel A. Bold histograms
indicate cells stained with biotinylated G-CSF-R antibodies and SA-PE; dotted
histograms: cells stained with SA-PE only. 
A
B
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fragment CH-296 (Takara Shuzo, Otsu, Japan) and preincubated with the
appropriate virus supernatant for 30 minutes at 37°C. Subsequently, bone marrow
cells (106 cells/ml) were mixed with fresh virus supernatant in a 1:1 ratio,
supplemented with a fresh cytokine cocktail and cultured overnight at 37°C and
5% CO2. Virus supernatant and cytokine cocktail were once again refreshed the
next day and the cells cultured for an additional 24 hrs. 
Progenitor cell assays and suspension culture
Bone marrow cells were plated in triplicate at densities of 1x105/mL in methyl
cellulose medium supplemented with 30% FBS, 1% BSA, 0.1mM 2-
mercaptoethanol, 2mM L-glutamine, and G-CSF (100 ng/ml). To calculate
infection efficiencies for the different receptor mutants, cells were also plated in
GM-CSF (20 U/ml) containing colony assays, with or without 2.5 µg/ml
puromycin (Sigma, Zwijndrecht, The Netherlands). Colonies (30 cells or more)
were counted on day 7 of culture. For cytological analysis and replating
experiments, colony cells were mass harvested and washed twice in HBSS.
Suspension cultures were performed in RPMI (Gibco BRL) supplemented with
10% FCS and 100 ng/ml G-CSF. Every 3- to 4 days, culture medium was
renewed and cells were counted on a Casy R-1 cell counter (Scharfe system,
Reutlinger, Germany). Cell densities were kept between 0.3 x 106 and 1x106/ml.
For inhibitor studies, cells were grown as described above, in the presence of
either 10 µM SB203580 or U0126 (Calbiochem, San Diego, CA) dissolved in
DMSO, or DMSO as a solvent control. Viable cells were counted daily and every
second day cells were spun down and resuspended in fresh media with fresh
inhibitor. Cell densities of proliferating cells were kept between 0.5 and 1.5 x 106
cells/ml. Cell viability was assessed by flow cytometric analysis (FACScan,
Becton-Dickinson, Sunnyvale, CA) using 7-amino actinomycin D (7-AAD;
Molecular Probes, Eugene Oregon, USA). 
Reporter assay for SOCS3 effects on G-CSF-R activity
To determine the effects of SOCS3 on the activity of G-CSF-R and mutants, we
employed a STAT5 luciferase assay essentially as described previously (40). In
brief, HEK 293 cells, seeded in 24-well dishes at 0.2 x 106 cells/well in 1 ml
DMEM/10% FCS, were cultured overnight and transfected by means of standard
CaPO4 precipitation with a mixture of the following plasmids: pME18S-STAT5
for expression of STAT5, a STAT5 luciferase reporter plasmid consisting of 5
repeats of the β-casein sequence upstream of a SV40 promoter in the pGL-3-
G-CSF and expansion of myeloid progenitor cells
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promotor vector (Promega, Madison, WI), a β-galactosidase expression plasmid
pRSVLacZ, derived from pCH110 (41), pcDNA3-SOCS3 (42) or empty
pcDNA3 (Invitrogen, Breda, The Netherlands) and pBabe with the different
G-CSF-receptor mutants. A volume of 100 µl precipitate with a total of 2 µg
DNA (400 ng of DNA for each construct) was added to each well. For SOCS3,
12.5 ng SOCS3 supplemented with 387.5 ng of pcDNA3 (empty vector) was
added. On day 4, the cells were stimulated for 6 hrs with 100 ng/ml G-CSF and
subsequently lysed in 100 ml lysis buffer (25 mM Tris phosphate pH 7.8, 15%
glycerol, 1% Triton X-100, 1 mM DTT, 8 mM MgCl2). To measure luciferase
activity, cell lysates (25 µl) were transferred to 96-well flat bottom plates (Costar,
Corning Inc, Corning, NY) and 25 µl of a 16 mg/ml luciferase substrate-
containing buffer (Steady-Glo luciferase assay System, Promega) was added to
each well. Emitted light was measured in a TopCount luminometer (Packard,
Meriden, CT). To correct luciferase activity levels for variations in transfection
efficiencies, 25 µl of cell lysate was incubated in parallel with 75 µl β-
galactosidase substrate buffer (100 mM Na-PO4 buffer pH 7.8, 10 mM KCl,
1 mM MgSO4, 2.7 mM DTT) and 0.56 mg/ml o-Nitrophenyl β-D-
galactopyranoside (oNPG, Sigma) for 15 minutes at 37°C. Absorption was
measured in a microplate reader (Biorad 450, Veenendaal, The Netherlands) at
450 nm. All experiments were performed in duplicate.
Results
Generation of gcsfr-deficient mice 
To inactivate the murine gcsfr gene, we constructed a targeting vector in which
the genomic sequence spanning exon 7-17 was replaced by a pgk-Neo selection
cassette (Figure 1A). Two independently isolated ES cell clones were injected
into blastocysts and the resulting chimeras were crossed with FVB-mice. Germ
line transmission of the knockout allele was achieved for both clones. Flow
cytometric analysis of bone marrow neutrophils using biotinylated G-CSF
confirmed the absence of G-CSF-R in gcsfr-/- mice and a 50% reduced
expression in gcsfr+/- mice (Figure 1B). In agreement with a previously reported
gcsfr knockout line (5), peripheral neutrophil counts in this gcsfr-/- strain are 15-
20% of levels found in WT littermates. 
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Role of receptor tyrosines in G-CSF-induced colony formation
To study the involvement of receptor tyrosines in G-CSF-R-mediated signaling
in primary hematopoietic cells, we introduced single tyrosine add back mutants,
mNull, G-CSF-R WT, or pBabe control vector (Figure 2), into gcsfr-/- bone
marrow cells and determined G-CSF responses in colony assays. As predicted,
no colonies were formed by gcsfr-/- cells transduced with pBabe vector (Figure
3A). Cells expressing mNull produced colonies at numbers equivalent to cells
transduced with G-CSF-R WT. At first glance, these data would suggest that the
receptor tyrosines are fully dispensable for G-CSF-controlled colony growth.
However, experiments with the add back mutants unveiled a more subtle
scenario. Expression of mA (Y704) slightly increased colony formation, while
G-CSF and expansion of myeloid progenitor cells
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Figure 3: Primary colony formation by gcsfr-/- bone marrow progenitors transduced
with different G-CSF-R constructs. Colonies were grown in the presence of  100 ng/ml
G-CSF. A) Mean colony numbers ± SD per 1000 infected bone marrow cells from triplicate
colony dishes; data are representative of 4 independent experiments. Colony numbers
were normalized to the numbers of infected cells based on puromycin resistance of CFU-
GM (responsive to GM-CSF) to correct for differences due to variations in transduction
efficiencies. B) mean numbers of cells per colony ± SD from triplicate dishes. 
A
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colony numbers obtained with mC (Y744) were similar to mNull. Colony
formation induced by mB (Y729) was reduced by approximately 50%, indicating
that Y729 has a negative influence on G-CSF-induced colony growth. The
presence of Y764 (mD) resulted in approximately 6-fold increase in cloning
efficiency. Assessment of the the mean number of cells per colony did not show
a correlation between colony number and size, except for mB (Figure 3B). The
latter observation suggests that negative signals emanating from Y729 affect both
clonogenicity as well as proliferative potential of the transduced progenitor cells.
Morphologic analysis revealed no differences in the composition of colonies
induced by the various receptor forms suggesting that the receptor tyrosines are
dispensable for G-CSF-induced differentiation (data not shown). 
G-CSF-R tyrosines are involved in G-CSF-dependent maintenance of myeloid
progenitor cell levels 
We next investigated to what extent G-CSF-R tyrosines contribute to the
expansion of the progenitor cells in serial replatings. As shown in Figure 4,
progenitor cells transduced with WT G-CSF-R maintained recloning abilities at
a relatively constant level up to the sixth replating. In contrast, replating abilities
of mNull expressing cells gradually declined after the third replating, suggesting
that receptor tyrosines are required for sustained G-CSF-dependent maintenance
and expansion of myeloid progenitor cells. The presence of Y729 (mB), Y704
48
Figure 4: Serial replatings of progenitor cells from gcsfr-/- bone marrow transduced
with G-CSF-R expression constructs.
Plating
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(mA), or Y744 (mC) further suppressed the recloning potential of progenitors. In
contrast, the presence of Y764 (mD) alone greatly enhanced recloning potential,
resulting in colony numbers after the fifth replating that were 100-fold higher
than WT and 10,000-fold higher than mNull expressing cells cultured in parallel.
The sustained expansion of progenitor cells mediated via Y764 also translated
into exponential cell proliferation in long-term suspension culture (Figure 5).
These expanded cells did not express mainly features of immature blast cells, but
rather represented a mixture of myeloid cell types at various stages of
differentiation. Notably, the cells remained fully dependent on G-CSF for
proliferation (data not shown). Cell numbers were maintained at relatively stable
levels in cultures from cells expressing WT and mNull G-CSF-R, whereas cells
expressing mA, mB or mC progressively lost proliferative abilities.
Proliferative signals from Y764 are mediated via ERK
Y764 is a docking site for connector proteins implicated in p21Ras/MAPK
signaling and has been shown to play a prominent role in the activation of ERK
as well as p38 MAP kinases (17, 24, 29). We therefore studied the effects of the
MEK1/2 inhibitor U0126, which blocks activation of ERK1 and ERK2, and the
p38 inhibitor SB203580 on G-CSF-induced proliferation of bone marrow cells
expressing mD in suspension culture. As shown in Figure 6, addition of U0126
to the cultures inhibited proliferation, while the effects of SB203580 were
minimal. These findings establish that ERK kinases are the principle mediators
of proliferative signaling via Y764 of the G-CSF-R. 
G-CSF and expansion of myeloid progenitor cells
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Figure 5: Expansion of gcsfr-/- bone marrow cells transduced with G-CSF-R expression
constructs in suspension culture. Cells were cultured in the presence of 100 ng/ml G-CSF.
Viable cell counts and replenishment of culture media were performed at 3- to 4 days intervals.
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SOCS3 inhibits G-CSF responses via Y729 of G-CSF-R
Recently, several studies have demonstrated that SOCS3 mediates its inhibitory
activity on a variety of cytokine receptors, e.g., leptin receptor and gp130, via
binding to receptor tyrosines (42, 43). Based on structural similarities between
G-CSF-R and gp130, we performed a G-CSF-R activity assay based on the onset
of STAT5-mediated gene expression, which is activated via the membrane
proximal region of G-CSF-R (27). Introduction of SOCS3 severely interfered
with activity of G-CSF-R WT (Figure 7). In contrast, under similar conditions,
activity of mNull was not affected, confirming that one or more of the receptor
tyrosines are involved in SOCS3 recruitment. Experiments with single tyrosine
add back mutants subsequently showed inhibition only with mB, suggesting that
Y729 is the major binding site for SOCS3. We suggest on the basis of these data
that the negative effects generated by Y729 on G-CSF-R signaling are mediated
by SOCS3. 
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Figure 7: STAT5-luciferase reporter assay showing prominent inhibitory effects of
co-transfection of pcDNA-SOCS3 on G-CSF-R WT and mB (Y729). Data are ex-
pressed as the percentage of activity measured after cotransfection of pcDNA3 empty
vector.
Figure 6: Effects of inhibitors of MEK (U0126) and p38MAPK (SB203580) on
proliferation of mD expressing cells.
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Discussion
The aim of this work was to investigate to what extent signals from G-CSF-R
tyrosines contribute to the G-CSF-induced responses of primary myeloid
progenitor cells. Previous studies in myeloid factor-dependent cell lines have
revealed that these tyrosines contribute to G-CSF-dependent proliferation,
differentiation and survival via signaling mechanisms involving the activation of
STAT3 and p21Ras (17, 21, 24, 25, 29, 44). Although these models have provided
useful information, it has also become clear that major discrepancies in signaling
requirements exist between cell lines and primary cells. For instance, STAT3 was
shown to induce growth arrest and neutrophilic differentiation in cell lines,
whereas a recent study in a transgenic mouse model demonstrated that STAT3 is
essential for G-CSF-induced proliferation of primary myeloid progenitors (40,
45, 46). The fact that certain mechanisms underlying growth factor-induced
proliferation of primary progenitor cells are bypassed or constitutively activated
in cell lines is likely to contribute to such differences. 
Some of the findings reported here are consistent with certain observations in cell
lines. For instance, Y764 confers hyperproliferative responses to G-CSF in both
primary progenitor cells and cell lines (25). However mNull, which was unable
to transduce proliferation signals in 32D cells, fully supported G-CSF-induced
colony formation of primary progenitors at plating efficiencies comparable to G-
CSF-R-WT. Thus, coupling of signaling mechanisms to G-CSF-R tyrosines in
primary myeloid progenitor cells is redundant for G-CSF-induced colony
growth. This might be attributed to either alternative activation of the pathways
linked to the tyrosines or to compensatory influences of other signaling
pathways. 
Although G-CSF-R tyrosines were not required per se for G-CSF-induced colony
formation, the experiments with the add back mutants clearly suggested that the
individual tyrosines exert regulatory functions. In particular, this applies to the
growth inhibitory role of Y729 and the growth promoting role of Y764. No
specific inhibitory pathway had previously been assigned to Y729. We have
identified Y729 here as the single tyrosine involved in SOCS3-mediated
inhibition of G-CSF signaling. In similar experiments we could not functionally
link SOCS1 or SOCS2 to Y729 (unpublished results). We hypothesize that
SOCS3 binds directly to Y729 via its SH2 domain. Y729 is located in a motif
G-CSF and expansion of myeloid progenitor cells
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(VLYGQLLGS) that shows striking homology with the SOCS3-SH2 binding
sites within gp130 and the leptin receptor. Characteristics of this motif are the
valine at pY-2, a hydrophobic residue at Y+3 and the serine at Y+6 (or Y+5) (42,
43). While this paper was under review, Hörtner et al. published data supporting
the notion that the Y729-containing motif of G-CSF-R indeed forms a direct
binding site for SOCS3 (47). Notably, G-CSF-R deletion mutants in patients with
severe congenital neutropenia that progress to acute myeloid leukemia lack this
motif (48-50), which may contribute to the hyperproliferative signaling
properties of these receptor forms (51, 52). 
The G-CSF-induced colonies grown from the gcsfr-/- bone marrow cells
transduced with G-CSF-R constructs were of granulocyte, granulocyte-
macrophage, macrophage or mast cell origin and contained fully mature cells. We
did not observe differences in the composition of the colonies grown from cells
transduced with G-CSF-R WT, tyrosine add back or tyrosine null mutants. This
argues against a major role of the receptor tyrosines in controlling myeloid
differentiation. A similar conclusion was recently drawn by Akbarzadeh et al.
(28), who further demonstrated that expression of myeloperoxidase and
gelatinase, enzymatic markers of granulocytic differentiation, was not affected
by substitution of the tyrosines. Interestingly, these authors observed a slight, but
significant, increase in the numbers of macrophage colonies and reduction of
granulocyte colonies with mutant Y729F, but not with their Y null mutant. This
suggests that Y729, possibly via recruitment of SOCS3, influences the balance
between granulocyte and macrophage colony growth only when pathways
activated via one or more of the remaining tyrosines remain intact. 
Both G-CSF and G-CSF-R deficient mice have reduced numbers of CFU-GM in
the bone marrow. Thus, G-CSF not only stimulates myeloid progenitors to
proliferate and differentiate towards neutrophils, but also controls the size of the
progenitor cell compartment in the bone marrow. The data from the sequential
platings suggest that signaling pathways emanating from the G-CSF-R tyrosines
contribute significantly to this control. The prominent stimulatory influence of
Y764 suggests that activation of the p21Ras/ERK pathway contributes to
progenitor cell expansion, whereas the inhibitory signal provided by Y729, most
likely involving SOCS3, has the opposite effect. Strikingly, Y704 and Y744,
while exerting no inhibitory effect on primary colony growth, suppressed
progenitor cell expansion in the replating experiments. The signaling pathways
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responsible for this inhibition are not known. Y704 and Y744 both function as
direct docking sites for STAT3 (25). STAT3 activation by G-CSF-R can also
occur in the absence of receptor tyrosines (13, 28). Still, we think that STAT3
activation via Y704 and Y744 may play an important role because depending on
the levels of activation in conjunction with other signaling pathways, STAT3 can
exert variable functions in myeloid progenitor cells. The effects of STAT3 on cell
proliferation and differentiation are diverse and depend on cell type and stage of
differentiation (40, 46, 53). Even within one cell type, unexpected variations in
the effects of STAT3, depending on the status of activation of other signaling
pathways, have been reported. Based on these findings a model was proposed in
which STAT3 orchestrates conflicting signals during G1 to S transition in the cell
cycle (54). In view of this more complex role of STAT3 in the regulation of cell
growth, we propose that STAT3 mediates stimulatory effects on primary colony
growth and neutrophilic differentiation, thereby negatively affecting the
expansion of myeloid progenitors controlled by G-CSF. Studies in which STAT3
activation in bone marrow cells can inducibly be inactivated are in progress to
unravel the full spectrum of activities of STAT3 in myeloid cell development. 
G-CSF and expansion of myeloid progenitor cells
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CHAPTER 3
Distinct activities of suppressor of cytokine signaling (SOCS)
proteins and involvement of the SOCS box in controlling 
G-CSF signaling
Gert-Jan M. van de Geijn, Judith Gits and Ivo P. Touw
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Summary 
Granulocyte colony-stimulating factor (G-CSF) induces proliferation of myeloid
progenitor cells and controls their differentiation into mature neutrophils. Signal
transducer and activator of transcription (STAT) proteins STAT3 and STAT5 are
activated by G-CSF and play distinct roles in neutrophil development.
Suppressor of cytokine signaling (SOCS) proteins are induced by STATs and
inhibit signaling through various negative feedback mechanisms. SOCS proteins
can compete with docking of signaling substrates to receptors, interfere with JAK
kinase activity and target proteins for proteasomal degradation. The latter process
is mediated through the conserved C-terminal SOCS box. We determined the role
of various SOCS proteins in controlling G-CSF responses and investigated the
involvement of the SOCS box therein. We show that SOCS1 and SOCS3, but not
CIS and SOCS2, inhibited G-CSF-induced STAT activation in HEK 293 cells. In
myeloid 32D cells, SOCS1 and SOCS3 are both induced by G-CSF. However,
relative to IL-3 containing cultures, during G-CSF-induced neutrophilic differen-
tiation SOCS3 expression was further elevated while SOCS1 levels remained
constant. SOCS box deletion mutants of SOCS1 and SOCS3 were severely
hampered in their abilities to inhibit STAT activation and to efficiently suppress
colony formation by primary myeloid progenitors in response to G-CSF. These
data demonstrate the importance of the SOCS box for the inhibitory effects of
SOCS proteins on G-CSF signaling and show that among the different SOCS
family members, SOCS3 is the major negative regulator of G-CSF responses
during neutrophilic differentiation.
Chapter 3
60
Chapter3v2 macv4.qxd  07-05-2004  01:14  Page 60
Introduction
Most hematopoietic growth factors and cytokines exert their action via
membrane receptors of the hematopoietin superfamily. Upon ligand binding,
these receptors activate JAK tyrosine kinases and subsequently one or more
members of the signal transducer and activator of transcription (STAT) protein
family (1). The expression of several suppressor of cytokine signaling (SOCS)
proteins, i.e., CIS, SOCS1 and SOCS3 is under the direct transcriptional control
of STATs (2-7). SOCS proteins, characterized by their SH2 domain and their
C-terminal SOCS box (8, 9), act in a classical negative feedback loop to inhibit
signaling from a variety of hematopoietic growth factors and cytokines including
Epo, IL-2, IL-3 and G-CSF (10-13). SOCS proteins can inhibit signaling via
multiple mechanisms. They may out compete other signaling substrates for
recruitment to a receptor (14). Alternatively, SOCS1 and SOCS3 can directly
inhibit JAK kinase activity utilizing their extended SH2 sub domains (ESS) and
their kinase inhibitory regions (KIR), two functional domains lacking in other
family members (15-17). SOCS1 has a high affinity for direct binding to JAKs
(18), whereas SOCS3 needs recruitment to receptor tyrosines for efficient
inhibition (11, 12, 19-21). A third proposed mechanism of inhibition by SOCS
proteins involves recruitment to the SOCS box of elongins B and C, which form
part of an E3 ubiquitin ligase complex, leading to subsequent proteasomal
degradation of signaling substrates (22, 23). The SOCS box may also regulate the
stability of the SOCS proteins themselves (23). Indeed, SOCS1, -2 and -3 are
highly unstable proteins, suggesting that active degradation is important for the
regulation of SOCS protein levels (24). It was shown that the SOCS box is
involved in proteasomal targeting of SOCS proteins (23, 25). However, the roles
of the SOCS box and elongin binding in SOCS protein degradation remain
controversial. Several reports have suggested that these interactions may actually
lead to SOCS protein stabilization (22, 26-29). 
G-CSF controls survival, proliferation and differentiation of myeloid progenitor
cells via multiple signaling mechanisms activated by the G-CSF receptor
(G-CSF-R). Among the different STAT family members, STAT3 and STAT5 are
most prominently activated by the G-CSF-R. STAT5 contributes to both G-CSF-
induced proliferation and survival of G-CSF-R transduced Ba/F3 cells (30).
STAT3 has been suggested to play a role in the regulation of the G1 arrest
required for neutrophilic differentiation, but not in the execution of the
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differentiation process itself (31). Studies in conditional STAT3 knockout mice
showed that removal of STAT3 resulted in neutrophilia, supporting the notion
that STAT3 is not essential for neutrophilic differentiation in vivo, but is required
for maintaining appropriately balanced neutrophil production (7). G-CSF failed
to upregulate SOCS3 transcripts in STAT3 deficient bone marrow cells,
suggesting that STAT3-induced SOCS3 is a major negative regulator of G-CSF-
controlled neutrophil production (7). Recent studies in mice lacking SOCS3 in
their hematopoietic cells or neutrophils also pointed towards a role for SOCS3 in
controlling G-CSF-induced neutrophil formation (32, 33). However, the
mechanism by which SOCS3 inhibits G-CSF-induced granulopoiesis was not
addressed in these studies. Generation of mice deficient for different members of
the SOCS family has revealed important functions of the SOCS proteins in
controlling signaling by multiple cytokines in hematopoietic and non-
hematopoietic cells (34-39). In addition to SOCS3, G-CSF induces the
expression of SOCS1, SOCS2, and CIS in hematopoietic cells (12, 40). The
ability of these additional SOCS proteins to suppress G-CSF-R signaling has not
been investigated.
Here, we report that both SOCS1 and SOCS3 inhibit G-CSF-induced STAT3 and
STAT5 activation, whereas CIS and SOCS2 do not. Rather, SOCS2 appeared to
exert an enhancing effect on activation of STAT3. In addition, we show that
transcription of SOCS3 is induced during G-CSF-stimulated neutrophilic
differentiation, while SOCS1 remains present at a relatively low and constant
level. Finally, using SOCS box deletion mutants, we demonstrate that the SOCS
boxes of SOCS1 and SOCS3 are important for efficient inhibition of STAT
activation and for inhibition of G-CSF-induced colony formation of primary
bone marrow cells. These data suggest for the first time an important role for the
SOCS box in SOCS-mediated inhibition of G-CSF-controlled granulopoiesis.
Material and methods
Constructs
Expression constructs of myc-tagged CIS, SOCS1, SOCS2 and SOCS3 in
pcDNA3 were provided by A. Yoshimura (18). The SOCS box deletion mutants
(SOCSdbox) were made by introduction of a stop codon before the SOCS box in
the SOCS1 and SOCS3 constructs using a site directed mutagenesis kit,
according to the manufacturer's instructions (Stratagene, La Jolla, CA). Primers
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used were for SOCS1: FmutSOCS1: 5'-cccgctgcgctagcgccgcgtg and
RmutSOCS1: 5'-cacgcggcgctagcgcagcggg; for SOCS3: FmutSOCS3: 5'-ctactc-
cgggggctagaagatccc and Rmut SOCS3: 5'-gggatcttctagcccccggagtag. All SOCS
constructs were cloned into the BamHI and SnaBI sites of retroviral vector pBabe
(41) and correct orientation of inserts was verified by nucleotide sequencing.
Human G-CSF-R wild type (WT) in the pBabe vector has been described before (13).
Cells and RNA isolation
Generation and culture of 32D cells stably expressing the G-CSF-R (32D/WT)
have been described previously (31). For short-term stimulation experiments, the
cells were washed twice with Hanks’ balanced saline solution (HBSS) and were
starved in RPMI at a concentration of 1 million cells/ml for 4 hrs and stimulated
with 100 ng/ml G-CSF for the indicated times. For growth on G-CSF, cells were
washed twice with HBSS to remove IL-3 and cultured in the presence of 10
ng/ml G-CSF for multiple days. At the indicated time points, cells were
harvested, resuspended in TRIzol® (Invitrogen, Breda, The Netherlands), snap
frozen and stored at -80°C. RNA was isolated according to manufacturer's
instructions. To remove genomic DNA, 5 µg of RNA was treated with 10 U of
DNAse I (Stratagene) in DNAse buffer (40 mM Tris-HCl pH7.5, 6 mM MgCl2,
2 mM CaCl2) for 1 hr at 37ºC.
Quantitative reverse transcriptase-PCR
For generation of cDNA, 1µg RNA was denatured at 65ºC for 5 minutes,
followed by 10 minutes on ice. First-strand buffer (250 mM Tris-HCl, pH8.3, 375
mM KCl, 15 mM MgCl2), dNTP's (1 mM final concentration), DTT (1 mM final
concentration), 40U Rnasin, 4 µg of random hexamers (Amersham Pharmacia,
Uppsala, Sweden) and 200U Superscript II reverse transcriptase (Invitrogen)
were added and the reaction was incubated at 42ºC for 2 hrs. Dilutions of cDNA
used for PCR amplification for SOCS1, SOCS3 and RNase inhibitor were 1:10,
1:30 and 1:60 respectively. Primers used for amplification of SOCS1 were
FTMSOCS1, 5'-tggtagcacgcaaccaggtg, and RTMSOCS1, 5'-tggcgaggacgaagac-
gag. For SOCS3, FTMSOCS3, 5'-tcaagaccttcagctccaa and RTMSOCS3, 5'-
tcttgacgctcaacgtgaag, were used. Primers for murine RNase inhibitor were:
forward, 5'-tccagtgtgagcagctgag, and reverse, 5'-tgcaggcactgaagcacca. Taqman
technology (PE Applied Biosystems, Model 7900 sequence detector, Foster City,
CA) was used for quantitative real-time PCR. The reactions were performed in a
volume of 25 µl of a mixture containing 2 µl of the respective cDNA dilution,
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primers at 0.2 µM and 12.5 µl of 2x SYBR green PCR Master mix (PE Applied
Biosystems) containing Amplitaq Gold® DNA polymerase, reaction buffer,
dNTP mix with UTP, and the double stranded DNA-specific fluorescence dye
SYBR green I. The PCR program used was 1 cycle of 2 minutes at 50ºC, 1 cycle
of 10 minutes at 95ºC, 45 cycles of denaturation for 15 s at 95ºC, annealing for
30 s at 62ºC and extension for 30 s at 62ºC. Samples were tested in duplicate and
the average values of the threshold cycle (Ct) were used for quantification. To
quantify the relative expression of SOCS1 and SOCS3, the Ct values were
normalized for endogenous reference (∆Ct = CtSOCS - CtRNase inhibitor) and compared
with a calibrator, using the ∆∆Ct method (Ct = CtSample - CtCalibrator). As calibrator
we used the expression in 32D cells deprived of growth factors and serum for 4
hours (Figure 2A) or the expression in 32D cells grown on IL-3 (Figure 2B). 
Luciferase assays
Luciferase assays were performed as described previously (13). In short, HEK
293 cells were transfected by CaPO4 precipitation (42) with a mixture of the
following plasmids: pME18S-STAT5 to obtain a robust STAT5 luciferase signal,
a β-casein-derived STAT5 luciferase reporter plasmid, pRSVLacZ, different
amounts of pcDNA3 with myc-tagged SOCS or empty pcDNA3 (Invitrogen) and
pBabe with WT G-CSF-receptor. For STAT3 luciferase experiments pME18S-
STAT5 was replaced by empty pcDNA3 and an m67-derived STAT3 luciferase
reporter was used (43). Twenty-four hours after transfection the medium was
replaced by serum free medium (DMEM + 0.1 % BSA). The next day the cells
were stimulated with G-CSF for 6 hrs, lysed and luciferase activity was measured
using Steady-Glo reagents (Promega Madison, WI). In parallel, the transfection
efficiency was determined using lacZ staining. Luciferase activity levels were
corrected for transfection efficiency using β-galactosidase expression levels. All
experiments were performed in triplicate.
Western blotting
Lysate from the luciferase assay was used in parallel for expression analysis of
myc-tagged SOCS proteins by Western blot. Antibodies used for detection were:
mouse anti-myc (9E10, Santa Cruz Biotechnology, Santa Cruz, CA) and goat
anti-actin (Santa Cruz Biotechnology).
Virus production and spot blot analysis
Phoenix E virus producer cells (a gift from G. Nolan, Stanford, CA) were
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transfected with pBabe-SOCS constructs by CaPO4 precipitation. Supernatants
containing high-titer, helper-free recombinant viruses were harvested from 80%
confluent producer cells grown for 16-20 hours in DMEM medium (with 10%
FCS and Penicillin/Streptomycin) and passed through a 45µm filter. To
determine titers of pBabe-SOCS and pBabe-EGFP viruses, the virus particles
were spun down by ultracentrifugation at 30.000 rpm (Beckman, Mijdrecht, The
Netherlands), and viral RNA was extracted with phenol (pH = 4.0) and spot-
blotted on nitrocellulose filters. This blot was hybridized with a pBabe-specific
probe (SV40 fragment, BamHI-HindIII digest). 
Infection of bone marrow progenitors with SOCS constructs
Hematopoietic cells were harvested from the femurs and tibiae of Fvb/N or 129/SV
mice (44). Prestimulation and retroviral transduction of the bone marrow cells
with pBabe SOCS expression constructs was performed as described before (13).
After the transduction procedure, bone marrow cells were plated in duplo at
densities of 0.5 and 2.0x105 cells per ml methyl cellulose containing medium
supplemented with 30% FBS, 1% BSA, 0.1mM 2-mercaptoethanol, 2mM
L-glutamine, with or without 1.5 µg/ml puromycin (Sigma, Zwijndrecht, The
Netherlands) and G-CSF (100 ng/ml). Colonies were counted on day 7 of culture.
Three independent experiments were performed with fresh virus supernatant in all cases. 
Results 
SOCS1 and SOCS3 inhibit G-CSF-induced STAT activation
CIS, SOCS1, SOCS2 and SOCS3 are the major SOCS proteins expressed in
hematopoietic cells (12, 40). We first assessed which of these proteins affected
G-CSF-induced STAT5 and STAT3 activity. SOCS1 and -3 inhibited G-CSF-
induced STAT5 luciferase activity in a dose-dependent manner. In contrast, CIS
and SOCS2 did not significantly affect STAT5 activity, even at the highest levels
of expression (Figure 1A). Similarly, SOCS1 and SOCS3 inhibited STAT3
luciferase reporter activity (Figure 1B), while CIS and SOCS2 had no inhibitory
effects. Rather, SOCS2 and to a lesser extent CIS, appeared to stimulate G-CSF-
induced STAT3 activation. 
G-CSF differentially induces SOCS1 and SOCS3 gene expression
SOCS1 and SOCS3 may be part of a G-CSF-induced negative feedback loop
activated during neutrophilic differentiation. To address this, we tested whether
and to what extent G-CSF controls the expression of SOCS1 and -3 during both
Distinct activities of SOCS proteins on G-CSF-R signaling
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short-term stimulation with G-CSF and upon G-CSF-induced neutrophilic
differentiation of 32D/WT cells. Stimulation with G-CSF results in a transient
upregulation of SOCS1 mRNA, whereas SOCS3 expression is more robust (Figure
2A). In addition, SOCS3 expression is induced over several days during
differentiation on G-CSF, while SOCS1 levels were comparable to values of
32D/WT cells cultured under proliferation conditions in the presence of IL-3 (Figure
2B). These results establish that SOCS3 is the most prominent SOCS member
involved in the negative feedback during G-CSF-induced neutrophilic differentiation
of myeloid cells.
Chapter 3
66
CIS (Myc)
SOCS3 (Myc)
SOCS2 (Myc)
SOCS1 (Myc)
0    12   25   100 ng DNA 0     6    25  100 ng DNA
A B
SOCS DNA (ng) SOCS DNA (ng)
0 50 100 0 50 100
F
ol
d 
in
du
ct
io
n 
S
TA
T
5-
lu
c
F
ol
d 
in
du
ct
io
n 
S
TA
T
3-
lu
c
Figure 1: G-CSF-induced activation of STAT5 and STAT3 is inhibited by SOCS1 and
SOCS3 but not by CIS and SOCS2. HEK293 cells were transiently transfected with WT-
G-CSF-R, STAT5 and lacZ expression constructs in combination with a STAT5 luciferase
reporter (A) or WT-G-CSF-R and lacZ expression constructs combined with a STAT3
luciferase reporter (B) and different amounts of CIS (x), SOCS1 (), SOCS2 () or
SOCS3 () DNA. G-CSF-induced luciferase activity was corrected for transfection
efficiency using lacZ staining and set at 100% in the absence of SOCS. Data shown are
mean ± SEM of at least 2 independent experiments with triplicate measurements. Lysate
of the luciferase assay was also used for Western blotting to detect expression of myc-
tagged SOCS proteins. 
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Role of the SOCS box in suppressing STAT3 and STAT5 activation
SOCS1 and SOCS3 are thought to inhibit cytokine signaling by interfering with
the phosphorylation of downstream signaling substrates of JAK kinases via their
KIR (16, 17). An alternative mechanism by which SOCS proteins may attenuate
signaling is by targeting critical signaling molecules for proteasomal
degradation, mediated via the SOCS box. To determine the involvement of the
SOCS box in the inhibitory effects of SOCS1 and SOCS3 we performed
luciferase reporter assays to test the activity of SOCS mutants lacking the SOCS
box (SOCS1dbox and SOCS3dbox) on G-CSF-R-induced activation of STAT5
and STAT3. Loss of the SOCS box of SOCS1 reduced inhibition of STAT5
activation (Figure 3A). In contrast, inhibition of STAT3 activity remained
essentially intact upon deletion of the SOCS box (Figure 3B). SOCS3dbox did
not inhibit STAT5 reporter activity at all, clearly showing that the SOCS box is
essential for the inhibitory effects of SOCS3 on STAT5 (Figure 3D). Suppression
of STAT3 activation by SOCS3 was also drastically reduced by deletion of the
SOCS box, although the effect was somewhat less pronounced than for STAT5
(Figure 3E). Western blot analysis revealed that upon transfection of comparable
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Figure 2: G-CSF stimulation of myeloid cells induces transient SOCS1 mRNA
expression whereas SOCS3 is induced during G-CSF-mediated neutrophilic
differentiation. 32D cells expressing the WT G-CSF-R were deprived of growth
factors for 4 hours and stimulated with G-CSF for the indicated times (A) or cultured in
the presence of G-CSF for three days (B). SOCS1 (black bars) and SOCS3 (gray bars)
mRNA expression levels were determined by quantitative RT-PCR and were normalized
using expression of ribonuclease-inhibitor. SOCS levels were expressed relative to growth
factor deprived 32D cells (A) or 32D cells cultured under proliferation conditions in IL-3
containing medium (B).
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amounts of expression plasmids, WT SOCS protein levels were consistently
higher than levels of SOCSdbox mutants (Figure 3, C and F). Upon titrating
down the amounts of transfected SOCS plasmids, protein expression of the
SOCSdbox mutants decreased more steeply than that of WT SOCS1 and -SOCS3.
These latter observations suggest that removal of the SOCS box reduces protein
stability of both SOCS1 and SOCS3. However, the amounts of SOCSdbox
protein at the highest concentrations tested were comparable with amounts of full
length SOCS1 and SOCS3 that already gave complete inhibition of STAT5
signaling. On this basis, we conclude that the reduced inhibition by SOCSdbox
mutants is not merely the result of decreased expression levels of the protein but
involves an intrinsic loss of its inhibitory capacity as a result of the removal of
the SOCS box.
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Figure 3: The SOCS boxes of SOCS1 and SOCS3 are important for inhibition of
STAT5 activation and to a lesser extent for inhibition of STAT3 activation by G-CSF.
STAT5 (A+D) and STAT3 (B+E) luciferase reporter assays with SOCS1 (), SOCS1dbox
(), SOCS3 () and SOCS3dbox () were performed as described in Figure 1. Average
± SEM out of at least three independent experiments is shown. In parallel Western blot
analysis of myc-tagged SOCS proteins and actin as a control for equal loading was
performed. Blots from representative experiments are shown in panels C and F.
Chapter3v2 macv4.qxd  06-05-2004  00:22  Page 68
Distinct activities of SOCS proteins on G-CSF-R signaling
69
The SOCS box of both SOCS1 and SOCS3 contributes to inhibition of G-CSF-
induced colony formation
To determine the contribution of the SOCS box to the inhibitory effects of
SOCS1 and SOCS3 on G-CSF-induced proliferation and differentiation of
primary hematopoietic cells, we introduced SOCS1 and SOCS3 and their SOCS
box deletion mutants in mouse bone marrow progenitor cells by retroviral gene
transfer. To assure that comparable viral titers were used for the various
infections, viral RNA was isolated from the supernatants and quantified using 
spot blot analysis with a vector specific cDNA probe. As shown in Figure 4A, the
viral RNA contents of the various supernatants were comparable, indicating that
the titers of the different retroviral vectors were similar. Introduction of SOCS1
and SOCS3 dramatically reduced G-CSF-induced colony numbers and size
compared with bone marrow cells transduced with EGFP-containing control
vector (Figure 4, B and C). The absence of the SOCS box resulted in a significant
relief of the inhibitory effects of SOCS1 and SOCS3 on the numbers and size of
CFU-G colonies. Thus, the SOCS box is also important for SOCS-mediated
suppression of G-CSF responses in primary myeloid progenitor cells.
Discussion
In this study, we investigated the role of the SOCS protein family members CIS,
SOCS1, SOCS2 and SOCS3 in G-CSF signaling. We showed that SOCS1 and -3
inhibited G-CSF-induced STAT3 as well as STAT5 activation, and no inhibition
by CIS and SOCS2 was detected. Additionally, we have demonstrated for the
first time a major role for the SOCS box in the inhibition of G-CSF-R signaling
by SOCS1 and SOCS3, in reporter assays and in primary bone marrow
progenitors. Upon the introduction of comparable amounts of DNA, the
expression of SOCSdbox mutants was consistently lower than that of WT SOCS
proteins (Figure 3). This supports a role for the SOCS box in stabilizing SOCS
protein levels. Similar conclusions were reported for SOCS1 and SOCS3 in
different model systems (26, 29). However, based on protein expression data
(Figure 3, C and F), we consider it unlikely that prevention of SOCS degradation
is the only contribution of the SOCS box to the inhibition of signaling. 
We observed that there are considerable differences between the abilities of
SOCS1dbox and SOCS3dbox to inhibit G-CSF-induced activation of STAT3 and
STAT5 (Figure 3). Although we currently have no explanation for these findings
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Figure 4: The SOCS box of SOCS1 and SOCS3 are required for efficient inhibition
of G-CSF-induced colony formation of bone marrow cells. A) RNA spot blot analysis
of supernatants containing pBabe retrovirus, demonstrating that titers used for infection
were comparable. B) CFU-G assay of primary bone marrow progenitor cells following
infection with pBabe EGFP and SOCS constructs. Cells were plated in methylcellulose
medium containing G-CSF (100 ng/ml) and puromycin (1.5 µg/ml). Data shown are mean
of at least two independent experiments + SEM. C) Photomicrographs of representative
examples of G-CSF colonies of transduced bone marrow cells (magnification 50x),
showing reduced colony size of SOCS transduced, but not SOCSdbox transduced cells
compared to control (EGFP-transduced) cells. 
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we anticipate that differences in recruitment mechanisms of SOCS1, SOCS3,
STAT3 and STAT5 to the activated G-CSF-R determine the outcome of deleting
the SOCS box on G-CSF signaling. It is clear that SOCS1dbox is a more potent
inhibitor than SOCS3dbox in both luciferase readouts. Conceivably, because of
its high affinity binding to JAKs, SOCS1dbox is able to recruit to JAKs and to
suppress signaling with the KIR independently of the SOCS box, even at reduced
expression levels. In addition, we showed that STAT3 activation is more sensitive
to inhibition by SOCS1dbox and SOCS3dbox than G-CSF-induced STAT5
activation. There are at least two explanations for this. STAT3 activation depends
to a significant extent on recruitment to tyrosines 704 and 744 of the G-CSF-R,
which first requires tyrosine phosphorylation of the receptor. This multistep
process might be more sensitive for inhibition than STAT5 activation, which is
mediated through direct recruitment to JAK itself (45). Reports on other cytokine
receptors corroborate this by demonstrating that the SOCS box is dispensable for
inhibition of STATs that require recruitment to receptor tyrosines for their
activation (15, 16). In addition, the difference between the downregulatory
effects of SOCS1dbox and SOCS3dbox on STAT3 versus STAT5 may relate to
differential involvement of regulatory proteins that are sensitive to proteasomal
targeting.
The turnover rate of STAT3 protein is low and phospho-STAT3 protein levels are
not affected by proteasomal inhibition, suggesting that proteasomal degradation
is not a major downregulatory mechanism for STAT3 (24, 46). Phosphorylated
STAT5 protein on the other hand, is stabilized by proteasomal inhibitors. As
ubiquitination or degradation of STAT5 protein was not detected, it was proposed
that a STAT5 phosphatase is present that is kept inactive by an unidentified
protein (46). Upon ubiquitination and proteasomal degradation of this protein,
the phosphatase would become active and dephosphorylate STAT5 (46). We have
recently shown that G-CSF induces binding of the SH2-containing tyrosine
phosphatase-2 (SHP-2) to STAT5, which depends on the presence of Y729 of the
G-CSF-R, a major docking site for SHP-2 (47). In view of the data showing that
SHP-2 functions as a STAT5 phosphatase (48, 49), these observations may point
to a scenario in which recruitment of SHP-2 contributes to STAT5 down-
regulation. Although the exact molecular features remain to be elucidated, these
findings are consistent with the model proposed by Wang et al. (46), implicating
a major role for proteasomal targeting in downregulation of STAT5 by the
degradation of a phosphatase inhibitory activity. 
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It is striking that, although inhibition by SOCS3dbox in the luciferase assays
was reduced compared to the effects of SOCS1dbox, SOCS3dbox still inhibited
G-CSF-induced colony formation to some extent whereas SOCS1dbox did not.
Although the reason for this difference is not clear, this may reflect inhibition of
effector mechanisms other than STATs that are involved in colony formation and
does not necessarily reflect direct effects of SOCS3dbox specific for G-CSF
signaling. 
We observed that SOCS2 (and to a lesser extent, CIS) dose dependently
stimulated G-CSF-induced STAT3 activation (Figure 1B). We currently have no
explanation for this stimulatory effect of SOCS2. A stimulatory role for SOCS2
has also been reported for other cytokine receptors. For instance, SOCS2
stimulated the activation of STAT5 by both the growth hormone receptor and the
prolactin receptor (50-52). It is interesting that the murine SOCS2 gene (cish2)
was recently identified as a frequent common retrovirus integration site in a
screen for novel leukemia genes. The virus integrations occurred 5' of the cish2
gene, which predictively results in the aberrant expression of SOCS2 transcripts
(53). In addition, SOCS2 is upregulated in chronic myeloid leukemia (CML)
cells in accelerated phase and in cell lines expressing the chimeric oncoprotein
Bcr-Abl characteristic of CML (54). These data suggest that SOCS2 can act as a
positive regulator of cytokine signaling and therefore might be considered an
oncoprotein rather than a negative regulator of growth, at least in hematopoietic cells.
In conclusion we demonstrated in this paper that SOCS1 and SOCS3, but not the
other SOCS family members expressed in hematopoietic cells, are capable of
inhibiting G-CSF-induced STAT activation. During G-CSF-induced neutrophilic
differentiation SOCS3 mRNA is upregulated whereas SOCS1 levels are
comparable to levels during proliferation on IL-3, suggesting that SOCS3 is the
most important SOCS family member for negative feedback during neutrophil
development. Our studies have unveiled a major role for the SOCS box in the
inhibition of G-CSF-induced colony formation of primary hematopoietic
progenitor cells, suggesting a role for proteasomal degradation mediated via
SOCS1 and SOCS3 in the downregulation of G-CSF responses during myeloid
cell proliferation and differentiation in a physiological context. 
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CHAPTER 4
G-CSF receptor truncations found in SCN/AML relieve
SOCS3-controlled inhibition of STAT5 but leave suppression
of STAT3 intact
Gert-Jan M. van de Geijn, Judith Gits, Lambertus H. J. Aarts,
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Abstract
Truncated granulocyte colony-stimulating factor receptors (G-CSF-R) are
implicated in severe congenital neutropenia (SCN) and consecutive development
of AML. Mice expressing G-CSF-R truncation mutants (gcsfr-d715) show
defective receptor internalization, an increased STAT5/STAT3 activation ratio
and hyper-proliferative responses to G-CSF treatment. We determined whether a
lack of negative feedback by suppressor of cytokine signaling (SOCS) proteins
contributes to the signaling abnormalities of G-CSF-R-d715. Expression of
SOCS3 transcripts in bone marrow cells from G-CSF-treated gcsfr-d715 mice
was approximately 60% lower than in wild type (WT) littermates. SOCS3
efficiently suppressed STAT3 and STAT5 activation by WT G-CSF-R in
luciferase reporter assays. In contrast, while SOCS3 still inhibited STAT3
activation by G-CSF-R-d715, STAT5 activation was no longer affected. This was
mainly due to loss of the SOCS3 recruitment site Y729, with an additional
contribution of the internalization defects of G-CSF-R-d715. Because Y729 is
also a docking site for the protein tyrosine phosphatase SHP-2, which binds to
and inactivates STAT5, we suggest a model in which reduced SOCS3 expression,
combined with the loss of recruitment of both SOCS3 and SHP-2 to the activated
receptor complex, determine the increased STAT5/STAT3 activation ratio and the
resulting signaling abnormalities projected by truncated G-CSF-R mutants.
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Loss of SOCS3 control on SCN-derived G-CSF-R mutants
Introduction
Granulocyte colony-stimulating factor receptor (G-CSF) is the major regulator of
neutrophil production, both under "steady state" conditions and during stages of
bacterial infections (1-3). G-CSF exerts its activity via a receptor (G-CSF-R) of
the hematopoietin receptor superfamily (4, 5). Typical of this class of receptors,
G-CSF-R has no intrinsic kinase activity but recruits cytoplasmic tyrosine
kinases of both the JAK and Src kinase families and activates signal transducer
and activator of transcription (STAT) proteins (6-11). G-CSF activates STATs 1,
3 and 5 (12-14). Whereas the contribution of STAT1 to G-CSF responses remains
unclear, STAT3 has been implicated in G-CSF-mediated growth arrest preceding
differentiation, while activation of STAT5 has been linked to proliferation and
survival signaling (15-17). Four tyrosine residues (Y704, Y729, Y744 and Y764)
in the G-CSF-R carboxy-terminus are involved in the recruitment of signaling
molecules, such as the adapter molecules GRB2 and SHC of the p21Ras-
MAPkinase pathway, and the protein tyrosine phosphatase SHP-2 (18-20). In
addition, activation of STAT3 depends on its recruitment to the G-CSF-R via
tyrosines 704 or 744 (20-22). At higher G-CSF-concentrations STAT3 can also
be activated in a tyrosine independent way via the G-CSF-R C-terminus (22, 23).
In contrast, activation of STAT1 and STAT5 is achieved via the membrane-
proximal region of G-CSF-R and does not require receptor tyrosine residues (13, 17).
In approximately 20% of patients suffering from severe congenital neutropenia
(SCN), G-CSF-R mutations are found that result in the expression of a G-CSF-R
with a truncated C-terminus (24, 25). These patients have an increased risk to
develop AML (25, 26). Activation of a G-CSF-R mutant truncated at amino acid
715 (G-CSF-R-d715) causes a hyperproliferative response in 32D cells, without
induction of neutrophilic differentiation (27). Mice with a targeted G-CSF-R-
d715 mutation show various degrees of neutropenia and their myeloid precursors
react to G-CSF administration with hyperproliferation, resulting in a sustained
neutrophilia (28, 29). Interestingly, transgenic (tg) mice overexpressing G-CSF-
R mutants truncated at amino acids (aa) 718 and 731, demonstrated increased
susceptibility to infection with Staphylococcus aureus, suggesting that
production of functional neutrophils is compromised in these animals (30).
Indeed, these tg mice had only one third of the peripheral neutrophil levels of
wild-type controls and their bone marrow showed increased percentages of
immature myeloid cells. 
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Functional analysis of truncated receptors revealed that a number of properties
are altered compared to WT G-CSF-R. Ligand-induced internalization of G-CSF-
R-d715 is severely affected due to the loss of 2 distinct motifs in the receptor C-
terminus that are important for internalization (27, 31, 32). G-CSF-R-d715 also
has a somewhat reduced ability to activate STAT3, possibly due to the loss of the
STAT3 recruitment site Y744 and the receptor C-terminus (22, 31). In contrast,
activation of STAT5 is strongly increased and is sustained after removal of G-
CSF, suggesting a prominent role for the C-terminus in mediating negative
feedback on STAT5 activation (17, 27, 31). Although the defective internalization
properties of truncated G-CSF-R forms contributed significantly to their
sustained signaling function, it was also clear that this did not fully explain these
findings (27, 32). In particular, the differential effects of receptor truncations on
the kinetics of STAT3 versus STAT5 activation remained unclear. 
Suppressor of cytokine signaling (SOCS) proteins are involved in the down
regulation of signaling from a number of hematopoietic growth factor receptors,
including G-CSF-R (33-36). A conserved SH2 domain and a C-terminal SOCS
box are characteristic for the SOCS family (reviewed in (37-39)). The expression
of most SOCS genes is controlled by STAT transcription factors (40-45). SOCS
proteins therefore act in a classical negative feedback loop to suppress cytokine
signaling. Three distinct inhibitory mechanisms have been linked to SOCS
proteins. CIS, founding member of the family, inhibits activation of STAT5 by
competing for STAT5 recruitment to phosphotyrosine motifs in e.g., the growth
hormone receptor (GH-R) and the erythropoietin receptor (Epo-R)(46, 47).
SOCS1 and SOCS3, on the other hand, directly suppress JAK kinase activity by
means of a kinase inhibitory region (KIR)(48-50). Upon recruitment to the
signaling complex via the SH2 domain of SOCS, the KIR mediates inhibition by
blocking access of both ATP and substrate to their binding sites in the catalytic
groove of JAK2 (49-53). Finally, SOCS proteins are also thought to down
regulate signaling via SOCS box-mediated targeting of signaling proteins for
proteasomal degradation (54, 55). An important difference between SOCS1 and -3
relates to how they are recruited into activated receptor complexes. Whereas the
SH2 domain of SOCS1 has a high affinity for, e.g., phosphorylated Y1007 in the
JH1 domain of JAK2, the affinity of the SH2 domain of SOCS3 for this residue
is much lower (49, 52, 56). Instead, SOCS3 is recruited with high affinity to
phosphotyrosine-based motifs in certain receptors and then subsequently
inhibits JAK activity via its KIR (34, 35, 48, 57-59). Importantly, for a number
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of cytokine receptors it has been established that the protein tyrosine phosphatase
SHP-2 and SOCS3 dock to identical tyrosine-based motifs with comparable
affinities (57-60). 
Studies in SOCS deficient mice have demonstrated major physiological roles for
SOCS proteins in controlling the levels of cytokine signaling in both non-
hematopoietic and hematopoietic cells (61-72). G-CSF induces the expression of
SOCS1, SOCS2, SOCS3 and CIS in hematopoietic cells (35, 73), but only
SOCS1 and SOCS3 appeared to inhibit G-CSF-induced STAT activation (74). In
two independent studies, Y729 of G-CSF-R was identified as the major
recruitment-site for SOCS3 (35, 36). Recently, it was reported that SOCS3 is a
key negative regulator of G-CSF-induced neutrophil production in vivo (75). 
In the present study, we investigated to what extent and by which mechanism(s)
truncation of the G-CSF-R C-terminus, as found in SCN, affects the negative
feedback regulation of G-CSF signaling by SOCS3. We show that truncation of
the G-CSF-R completely relieved the inhibitory effects of SOCS3 on activation
of STAT5. In striking contrast, the suppressive effects of SOCS3 on G-CSF-R-
d715-induced activation of STAT3 were hardly affected by the truncation. These
findings provide a new mechanistic explanation for the increased ratio of
STAT5/STAT3 activation in gcsfr-d715 mice, which has previously been linked
to the shift in the proliferation/differentiation balance in the myeloid progenitor
cell compartment found in these animals (31).
Material and methods
Expression constructs
The constructs of human G-CSF-R WT, d715, Y729F, d735, d749-769, d715-
735, and the GFP-G-CSF-R fusions in the pBabe vector (76) have been described
before (18, 20, 32, 36) (see Figure 1A). The d735F and d749-769F mutants were
generated from mutant Y729F, by introduction of a stop codon or by deletion of
region 749-769 respectively, with a site-directed mutagenesis kit according to the
manufacturers instructions (Stratagene, La Jolla, CA). Expression constructs of
myc-tagged SOCS1 and SOCS3 in pcDNA3 were a gift from A. Yoshimura (56).
For expression of SHP-2, HA-tagged human SHP-2 was cloned into the EcoRI -
XhoI sites of expression vector pSG5 (77). For expression of STAT5, pME18S-
STAT5B was used (78).
Loss of SOCS3 control on SCN-derived G-CSF-R mutants
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Bone marrow cells and isolation of RNA
WT and gcsfr-d715 mice (28) were stimulated daily for 4 days with G-CSF or
received solvent only. Each experimental group contains 2 mice of each
genotype. Bone marrow cells were isolated, resuspended in TRIzol® RNA
extraction reagent (Invitrogen, Breda, The Netherlands), snap frozen and stored
at -80ºC (28). For the in vitro stimulation, bone marrow cells were harvested
from two WT and two gcsfr-d715 mice that had not been treated with G-CSF.
Cells were cultured for 1 hr in HBSS (Invitrogen) with 5% FCS, non-adherent
cells were taken and starved for 4 hrs in RPMI (Invitrogen) + 0.5% BSA. Cells
were stimulated for the indicated periods with G-CSF (100 ng/ml) and
resuspended in Trizol. RNA was isolated according to manufacturer's instructions
and subsequently treated with DNAse to remove genomic DNA. DNAse
treatment of 5 µg of RNA was performed in DNAse buffer (40 mM Tris-HCl
pH7.5, 6 mM MgCl2, 2 mM CaCl2) with 10 U of DNAse I (Stratagene) for 1 hr
at 37ºC.
Quantitative RT-PCR
To generate cDNA, 1µg RNA was denatured at 65ºC for 5 minutes followed by
10 minutes on ice. After addition of first-strand buffer (250 mM Tris-HCl, pH8.3,
375 mM KCl, 15 mM MgCl2), with dNTP's (1 mM final concentration), DTT (1
mM final concentration), 4 µg random hexamers (Amersham Pharmacia,
Uppsala, Sweden), 40U RNasin and 200U Superscript II reverse transcriptase
(Invitrogen), the reaction was incubated at 42ºC for 2 hrs. The cDNA was diluted
1:10, 1:30 and 1:60 for SOCS1, SOCS3 and RNase inhibitor respectively before
PCR amplification. Primers used for amplification of SOCS1 were FTMSOCS1:
5'-tggtagcacgcaaccaggtg and RTMSOCS1: 5'-tggcgaggacgaagacgag, and for
SOCS3: FTMSOCS3: 5'-tcaagaccttcagctccaa and RTMSOCS3: 5'-tcttgac-
gctcaacgtgaag. Primers for murine RNase inhibitor were forward 5'-tccag-
tgtgagcagctgag, and reverse 5'-tgcaggcactgaagcacca. For the quantitative real-
time PCR, Taqman technology was used (PE Applied Biosystems, Model 7900
sequence detector, Foster City, CA). The reactions were performed in a volume
of 25 µl of a mixture containing 2 µl of the respective cDNA dilution, primers at
0.2 µM and 12.5 µl of 2x SYBR green PCR Master mix (PE Applied Biosystems)
containing Amplitaq Gold® DNA polymerase, reaction buffer, dNTP mix with
UTP, and the double stranded DNA-specific fluorescence dye SYBR green I. The
PCR program used was 1 cycle of 2 minutes at 50ºC, 1 cycle of 10 minutes at
95ºC, 45 cycles of denaturation for 15s at 95ºC, annealing for 30 s at 62ºC and
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extension for 30 s at 62ºC. To determine the expression levels, samples were
tested in duplicate and the average values of the threshold cycle (Ct) were used
for quantification. To quantify the relative expression of SOCS1 and SOCS3, the
Ct values were normalized for endogenous reference (∆Ct = CtSOCS - CtRNase
inhibitor) and compared with a calibrator, using the ∆∆Ct method (Ct = CtSample -
CtCalibrator). As calibrator for G-CSF stimulation in vivo we used the expression in
WT bone marrow of unstimulated mice. As calibrator for the in vitro stimulation
we used expression after 4 hours of starvation. 
Luciferase assays
Luciferase assays were performed as described previously (36). In short, HEK
293 cells, grown in 24 well plates, were transfected by the calcium phosphate
precipitation method with a mixture of the following plasmids. For STAT5-
luciferase experiments: expression vector pME18S-STAT5, a β-casein-derived
STAT5 luciferase reporter plasmid, a β-galactosidase expression plasmid
pRSVLacZ, a pBabe construct with WT or mutant G-CSF-R (Figure 1A) and
different amounts of pCDNA3 with myc-tagged SOCS or empty pcDNA3
(Invitrogen). For the STAT3-luciferase experiments pME18S STAT5 was
replaced by pcDNA3 vector and an m67-derived STAT3 luciferase reporter was
added instead of the STAT5 reporter. A volume of 100 µl calcium phosphate
precipitate with in total 2 µg DNA was added to each well. With the exception of
SOCS3, 400 ng of DNA for each construct was added per well. Different
amounts of pcDNA3-SOCS3 were added, supplemented with empty pcDNA3
vector up to 400 ng. After 24 hours the cells were starved overnight in DMEM +
pen/strep + 0.1% BSA. The next day, the cells were stimulated with 250 ng/ml
G-CSF for 6 hrs, lysed and assayed for luciferase activity using Steady-Glo
reagents (Promega, Madison, WI). In parallel, the transfection efficiency was
determined using lacZ staining. Luciferase activity levels were corrected for
transfection efficiency using β-galactosidase expression levels. All
experiments were performed in triplicate. Fold induction by G-CSF was
calculated and set at 100% in the absence of SOCS. For inhibitor studies, the Src
inhibitor PP-2, the JAK inhibitor WHI-P154 (Calbiochem, San Diego, CA) or
DMSO as a solvent control was added to the cells 1 hr prior to G-CSF-
stimulation. Unless stated otherwise, data were analyzed by means of ANOVA.
To compare G-CSF-R expression levels, transfected cells were stained with
biotinylated mouse anti human G-CSF-R antibody (Pharmingen, San Diego, CA)
followed by phycoerythrin-conjugated streptavidin (SA-PE; Caltag laboratories, 
Loss of SOCS3 control on SCN-derived G-CSF-R mutants
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Burlingame, CA) and analyzed by flow cytometry (FACS-Calibur, Becton
Dickinson, Sunnyvale, CA). As shown in Figure 1B, G-CSF-R expression is
detectable with increased (less than 1 log unit) expression of the internalization-
defective mutants (G-CSF-R-d715, d749-769 and d749-769F). As previously
reported, this difference is mainly due to decreased spontaneous internalization
of these mutants in the absence of G-CSF in non-myeloid cells (32). 
84
Chapter 4
Figure 1: Expression of WT and mutant G-CSF receptors. A) Schematic repre-
sentation of the intracellular domain of the G-CSF receptor and mutants. Boxes 1 and
2 represent subdomains conserved in the hematopoietin receptor superfamily. The
open box indicates the deleted region in G-CSF-R-d749-769 and G-CSF-R-d715-735.
B) Flow cytometric analysis of the expression levels of the different G-CSF-R forms used
in luciferase reporter assays. Bold histograms indicate cells stained with biotinylated G-
CSF-R antibodies and SA-PE; shaded histograms: cells stained with SA-PE only; e.v.:
cells transfected with empty vector.
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Immunoprecipitations and Western blotting
Phoenix E cells (a gift from G. Nolan, Stanford, CA) were transfected with G-
CSF-R, SHP-2 and in the case of the SHP-2-STAT5 co-immunoprecipitations, as
well with the STAT5 expression construct. After 24h the media was replaced by
DMEM + 0.1% BSA. The next day, cells were stimulated for 10 minutes with G-
CSF, washed twice with cold PBS and lysed in lysisbuffer containing 20 mM
Tris-HCl pH8.0, 137 mM NaCl, 10 mM EDTA, 100 mM NaF, 1% NP40, 10%
glycerol, 2 mM Na3VO4 and 1 mM Pefablock SC, 50 µg/m1 aprotinin, 50 µg/ml
leupeptin, 50 µg/ml bacitracin and 50 µg/ml iodoacetamide as protease
inhibitors. Immunoprecipitations with anti-HA antibody and protein G-sepharose
beads (Sigma, Zwijndrecht, The Netherlands) and subsequent Western blotting
were performed as described previously (7). Antibodies used were mouse anti-
HA (Santa Cruz Biotechnology, Santa Cruz, CA), rabbit anti-SHP-2 (Santa Cruz
Biotechnology), mouse anti-green fluorescent protein (Roche, Almere, The
Netherlands) and rabbit anti-STAT5B (Santa Cruz Biotechnology).
Results
Reduced G-CSF-induced SOCS3 expression in gcsfr-d715 mice 
SOCS proteins are under the transcriptional control of STATs (41, 43, 44, 79).
Because G-CSF-R-d715 shows altered activation of STAT3 and STAT5
compared to WT G-CSF-R (27, 31), we first investigated expression of SOCS1
and -3 in WT versus gcsfr-d715 mice under steady state conditions and after daily
treatment of the animals with G-CSF for 4 days. As shown in Figure 2A, steady
state levels of SOCS1 in gcsfr-d715 mice and their WT littermates were
approximately similar. Also after G-CSF treatment, SOCS1 transcript levels in
WT and gcsfr-d715 mice had not changed dramatically. A slight (2.5-fold)
increase in SOCS1 mRNA levels in gcsfr-d715 mice compared to WT animals
was noted (Figure 2A). In contrast, SOCS3 expression was strongly (>12-fold)
induced by G-CSF in WT mice, while expression levels in gcsfr-d715 mice
reached only about 30% of these levels both after G-CSF stimulation as well as
in steady state (Figure 2B). In addition we isolated bone marrow cells from
untreated WT and gcsfr-d715 animals and stimulated them with G-CSF in vitro.
As shown in Figure 2C, stimulation with G-CSF gives a strong induction of
SOCS3 mRNA. Again, SOCS3 transcript levels are reduced in G-CSF-R-d715
cells upon stimulation with G-CSF. This demonstrates that the reduced upregulation
of SOCS3 mRNA also occurs outside the bone marrow compartment and is due to
Loss of SOCS3 control on SCN-derived G-CSF-R mutants
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altered signaling in the G-CSF-R-d715 cells. These results establish that SOCS3
is the principle SOCS protein induced by G-CSF and that C-terminal truncation
of the G-CSF-R results in a significantly reduced ability of the receptor to
induce SOCS3. 
G-CSF-R truncation relieves the suppressive effects of SOCS3 on G-CSF-
induced STAT5 but not STAT3 activation
We next studied the consequences of SOCS3 expression on G-CSF-induced
activation of STAT5- and STAT3-luciferase reporter constructs in HEK293 cell
transfectants expressing either WT G-CSF-R or G-CSF-R-d715. G-CSF-induced
86
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Figure 2: Reduced SOCS3 but not SOCS1 expression in gcsfr-d715 mice. WT mice
and gcsfr-d715 littermates were injected with vehicle or G-CSF for four consecutive days.
RNA was isolated and SOCS1 (A) and SOCS3 (B) transcript levels were measured by
quantitative RT-PCR. Expression of RNase inhibitor was used for normalization of the
data. SOCS levels were expressed relative to untreated WT mice. Data shown are
mean + SEM of three experiments (*: Difference between WT and gcsfr-d715 animals is
significant, Students’ t-test: p< 0.05). C) SOCS3 expression in isolated bone marrow cells,
growth factor-deprived for 4 hrs and then stimulated with G-CSF in vitro for the indicated
times. SOCS3 levels were expressed relative to growth factor-deprived cells. Data shown
are mean + SEM of four experiments, difference between WT and G-CSF-R-d715 is
significant (Students’ t-test: p<0.05). 
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STAT5 activity by WT G-CSF-R was dose dependently inhibited by SOCS3 (Figure
3A). In contrast, STAT5 activity induced by G-CSF-R-d715 was not affected, even at
the highest expression levels of SOCS3. This finding can be reconciled with recent
reports showing that Y729 in G-CSF-R is the major docking site for SOCS3, a
residue that is lacking in G-CSF-R-d715 (35, 36). Surprisingly, STAT3 activation by
G-CSF-R-d715 remained highly sensitive to inhibition by SOCS3 (Figure 3B). These
data establish that Y729, while essential for downregulation of STAT5, is dispensable
for the inhibitory effects of SOCS3 on G-CSF-induced STAT3 activation.
Differential effects of SOCS3 on G-CSF-R-d715-mediated STAT3 and STAT5
activation are not due to distinct involvement of upstream tyrosine kinases
G-CSF-R activates the Janus kinases JAK1, JAK2 and Tyk2, but also the Src
kinases Lyn and HCK (6-8, 10, 11). Both the JAK and Src kinases can
phosphorylate STAT proteins in hematopoietic cells (80, 81). Importantly, SOCS
proteins differentially affect these kinases: in contrast to JAK kinases, the Src
kinase Lyn is insensitive to SOCS-mediated inhibition (82). We considered a
possible scenario in which JAK and Src kinases are differentially involved in the
activation of STAT3 and STAT5. In that hypothetical context, G-CSF-induced
STAT5 activation by G-CSF-R-d715 would become SOCS-insensitive because,
Loss of SOCS3 control on SCN-derived G-CSF-R mutants
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Figure 3: STAT5 activation by the G-CSF-R-d715 is insensitive for inhibition by
SOCS3 whereas STAT3 activation is not. HEK 293 cells transfected with STAT5 or
STAT3 luciferase reporter constructs were stimulated with G-CSF for 6 hours and assayed
for luciferase activity. G-CSF-induced STAT5 (A) or STAT3 (B) luciferase reporter activity
in the absence of SOCS3 was set at 100%. Data are expressed as mean + 95%
confidence interval of four independent experiments. (*: differences between WT and G-
CSF-R-d715 are significant; p<0.01).
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as a result of the truncation of the receptor C-terminus, involvement of Src
activity in the activation of STAT5 might become prevalent. To investigate this
possibility, we performed the STAT reporter experiments in the presence of the JAK
inhibitor WHI-P154 (83) or the Src inhibitor PP-2 (84). Both STAT3- and STAT5-
induced luciferase activity was inhibited by WHI-P154, but not by PP-2, indicating
that JAK, but not Src-kinase activity is essential for G-CSF-induced activation of
both STAT3 and STAT5 by the WT G-CSF-R (Figure 4). Notably, this remained
essentially unchanged when activation was induced via G-CSF-R-d715. Although
PP-2 slightly reduced STAT5 activation, G-CSF-R-d715 signaling was still
completely dependent on JAK activity. 
88
Figure 4: Effects of JAK and Src inhibitors on STAT5 and STAT3 activation by WT
G-CSF-R and G-CSF-R-d715. Luciferase assays were performed as in Figure 3. One
hour before initiation of STAT5 (A) and STAT3 (B) luciferase reporter assays, the Src
inhibitor PP-2 or the JAK inhibitor WHI-P154, dissolved in DMSO, were added to the cells
at concentrations indicated. Solvent control cells were treated with DMSO only. Data are
expressed as mean + SEM of three independent experiments (*: difference with DMSO-
treated control of same group is significant, p<0.05). 
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These results thus exclude the possibility that, in the case of G-CSF-R-d715, the
loss of SOCS-mediated inhibition of STAT5 signaling is caused by altered
involvement of tyrosine kinases (e.g., Lyn instead of JAK) as a consequence of
the receptor truncation. We have previously published data from EMSA assays
showing that activation of STAT3 by G-CSF-R-d715 is decreased compared to
the WT G-CSF-R when measured between 0-60 minutes after stimulation. This
is due to the partial lack of STAT3 recruitment mechanisms (31). We observed
that activation of STAT3 by G-CSF-R-d715 in the luciferase reporter assay was
increased relative to the WT G-CSF-R (Figure 4B). This could be directly linked
to the defective receptor internalization of G-CSF-R-d715 (data not shown).
Apparently, the internalization defect of G-CSF-R-d715 causes reduced off-
switch of signaling, which results in increased accumulation of luciferase activity
during the 6 hr time period of the experiment. However, despite this increased
STAT3 activation this signal remains fully sensitive for inhibition by SOCS3
(Figure 3B and 4B).
Defective G-CSF-R internalization reduces sensitivity to SOCS3 only when
combined with the loss of Y729
G-CSF-R-d715-induced STAT5 activation was considerably more resistant to the
suppressive effects of SOCS3 than was the case for a full length G-CSF-R mutant
lacking the SOCS3 docking site Y729, e.g., G-CSF-R-Y729F (Figure 5). This
could be suggestive of a second, tyrosine independent mechanism of SOCS3
recruitment via the G-CSF-R C-terminus or relate to defective ligand-induced
internalization of G-CSF-R-d715 (27, 31, 85). To directly address this issue, we
compared the SOCS3 sensitivity of WT G-CSF-R and G-CSF-R-d715 with that
of G-CSF-R-d749-769 (Figure 1A). This mutant is as defective in internalization
as G-CSF-R-d715, due to the lack of two internalization domains (32). As shown
in Figure 5, SOCS3 inhibits G-CSF-R-d749-769 as effectively as WT G-CSF-R,
indicating that the loss of receptor internalization per se does not alleviate STAT5
inhibition by SOCS3. However, mutation of the SOCS3 recruitment site Y729 in
this internalization defective mutant (G-CSF-R-d749-769F) resulted in a
complete loss of SOCS3-mediated STAT5 inhibition. These results provide
evidence for two distinct mechanisms of SOCS3 recruitment to the G-CSF-R,
one that is independent of internalization (via Y729) and one that requires
internalization. Possibly this latter mechanism involves direct interaction of
SOCS3 to JAKs. Both of these mechanisms are disrupted in G-CSF-R-d715
(Figure 5). 
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Y729 is a combined recruitment site for SOCS3 and SHP-2
For a number of receptors it has been demonstrated that SOCS3 recruitment sites
are also SHP-2 docking sites (57-60). By combined immunoprecipitation (IP)
and Western-blotting (WB), we tested whether SHP-2 binds to Y729 of G-CSF-
R. We performed these experiments with GFP-tagged receptor constructs and
used anti-GFP antibodies for immune detection. The GFP-tagged receptors were
shown to behave identically as untagged receptors with respect to proliferation,
differentiation and activation of STAT3 and STAT5 (32). Stimulation with G-
CSF induced co-immunoprecipitation of SHP-2 with the WT-G-CSF-receptor
(Figure 6A, lanes 1 and 2). Truncation of the receptor at aa 715 resulted in a
complete loss of the interaction with SHP-2 whereas truncation at aa 735 did not
affect the SHP-2-G-CSF-R interaction (Figure 6, lanes 3 and 4). This result
strongly supports the notion that Y729, the only tyrosine present in this region, is
a binding site for SHP-2. To determine the relative contribution of Y729 to SHP-
2 recruitment to full length G-CSF-R, we also tested G-CSF-R mutant d715-735
(Figure 1) in co-immunoprecipitations. Although this mutant demonstrated a
significantly reduced SHP-2 binding compared to WT G-CSF-R, it clearly bound
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Figure 5: Reduced internalization of truncated G-CSF-R mutants alleviates
inhibition by SOCS3 only in the absence of Y729. Comparison of G-CSF-R mutants
with normal (WT and Y729F) and defective (d715, d749-769 and d749-769F)
internalization kinetics for sensitivity to SOCS3-mediated inhibition of STAT5 luciferase
reporter activity. STAT5 luciferase reporter assay was performed as described in Figure 3.
Data are expressed as mean of at least two independent experiments with triplicate
measurements. (*: difference between WT and d749-769 versus all other G-CSF-R
mutants is significant, p< 0.01. #: difference between Y729F and d749-769F: p = 0.07. φ:
difference between Y729F versus d715 and d749-769F is significant p<0.02).
*
* *
#
φ
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more SHP-2 than did G-CSF-R-d715 (Figure 6, lane 5). Taken together, these
results support the notion that Y729 of G-CSF-R forms a combined SOCS3 and
SHP-2 recruitment site and show that an alternative mechanism of SHP-2
binding to the C-terminal region (aa 736-813) of G-CSF-R exists. The latter
mechanism possibly involves recruitment of SHP-2 via Y764 (20).
Y729 of the G-CSF-R is required for the formation of a SHP-2-STAT5 complex
It was recently shown that SHP-2 can interact with STAT5, resulting in
dephosphorylation and inactivation of STAT5 (86, 87). Given the requirement of
Y729 for recruitment of SHP-2 to the G-CSF-R, we investigated if the formation
of a SHP-2-STAT5 complex would be dependent on the presence of Y729 of the
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Figure 6: SHP-2 associates with distinct regions of the G-CSF-R and Y729 is
required for the formation of a SHP-2-STAT5 complex. A) HA-SHP-2 immuno-
precipitations (IP) of Phoenix E cells expressing GFP-tagged G-CSF-R mutants. Cells
were starved overnight (-) and stimulated for 10 minutes with G-CSF. As a control,
expression of GFP-G-CSF-R and SHP-2 in whole cell lysate (WCL) is shown in the lower
two panels. B) HA-SHP-2 IP's of Phoenix E cells expressing different G-CSF-R mutants
and STAT5 were performed as described in Figure 6A. Lane 7 is a HA-IP in the absence
of HA-SHP-2 demonstrating the specificity of the IP.
WT d735 WTd735F
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G-CSF-R as well. As shown in Figure 6B, stimulation of the WT and G-CSF-R-
d735 indeed results in co-immunoprecipitation of STAT5 with SHP-2 (lanes 1 to
4). However, in the absence of Y729 formation of this complex is disrupted (lane
5 and 6), demonstrating the importance of Y729 of the G-CSF-R for the
formation of a SHP-2-STAT5 complex. 
Discussion
We investigated whether and by which mechanism(s) altered susceptibility to the
inhibitory effects of SOCS proteins contributes to the hyperproliferative
signaling of G-CSF-R C-terminal truncation mutants, which are frequently found
in SCN patients with disease progression towards AML (24-26). We first
concentrated on the regulation of expression of SOCS1 and SOCS3, which
represent the SOCS family members with the most prominent negative effects on
G-CSF signaling (74). Both SOCS1 and SOCS3 promoters contain STAT binding
sites (41, 43, 44, 79) and dominant negative STAT3 blocks SOCS1 as well as
SOCS3 mRNA expression, indicating that both SOCS genes are transcriptional
targets of STAT3 (41). STAT1 also binds to the SOCS3 promoter (44), but STAT3
is the major STAT protein involved in SOCS3 induction by G-CSF. This was
demonstrated most clearly in conditional STAT3 knock-out mice which also
lacked G-CSF-induced upregulation of SOCS3 (45). Because the loss of the G-
CSF-R C-terminus affects both intensity and duration of the activation of STATs,
we investigated SOCS1 and SOCS3 transcript levels in WT and gcsfr-d715 mice,
both before and after 4 days of G-CSF treatment of the mice. G-CSF treatment
of WT animals did not affect SOCS1 transcript levels. Receptor truncation
resulted in a modest increase in SOCS1 expression after G-CSF stimulation,
possibly due to the increased STAT5 activation by G-CSF-R-d715 (31). This is
in agreement with data showing that IL-3-induced SOCS1 expression is almost
completely abrogated in the presence of dominant negative STAT5 (88).
SOCS3 mRNA levels on the other hand, increased more than 12-fold in
response to G-CSF. SOCS3 levels in gcsfr-d715 mice were clearly lower than in
their WT littermates during "steady state" and upon stimulation with G-CSF in
vivo or in vitro. These results establish that distinct regulatory mechanisms
for upregulation of SOCS1 and SOCS3 expression exist in the context of the
G-CSF-R. Recent studies with conditional STAT3 and SOCS3 knockout
strains demonstrated that the levels of neutrophilia in these mice in
response to G-CSF treatment are similar to those observed in gcsfr-d715 mice
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(28, 29, 45, 75). This would support the hypothesis that the loss of the negative
feedback loop involving STAT3-controlled induction of SOCS3 might suffice to
explain the gcsfr-d715 phenotype. However, in view of previous data showing
that STAT3 activation in gcsfr-d715 mice is only moderately and temporarily
reduced (31), it is conceivable that factors other than STAT3 also contribute to G-
CSF-induced SOCS3 expression. 
In addition to the reduced expression of SOCS3 in the gcsfr-d715 mice, the
truncated G-CSF-R lacks Y729, which is the major recruitment site for SOCS3
(35, 36). While this provided an obvious second mechanism by which the
truncated G-CSF-R forms bypass the suppressive effects of SOCS3, this applied
to the activation of STAT5 but not STAT3, which still remained SOCS3 sensitive
(Figure 3). This result provides a likely explanation for the increased ratio of
STAT5/STAT3 activation by G-CSF-R-d715, which has been linked to shifting
the proliferation/differentiation balance towards proliferation and extended cell
survival (31). Two potential explanations, i.e., differential involvement of
upstream tyrosine kinases and differential sensitivity due to altered
internalization kinetics were shown to play respectively no or only a limited role
in this study. For efficient activation of STAT3, first G-CSF-R tyrosine
phosphorylation is required, which creates STAT3 recruitment sites. This
indicates that activation of STAT3 is a multistep process. It is conceivable that
inhibition of STAT3 is still achieved when recruitment of SOCS3 is suboptimal
due to the lack of Y729. In contrast, inhibition of STAT5, which is activated
through direct interaction with JAK kinases (89), may require optimal SOCS3
recruitment for complete inhibition. STAT5 activation by G-CSF-R mutant
Y729F was inhibited to a considerable extent at the highest levels of SOCS3,
which is probably mediated through low affinity interaction of SOCS3 and JAKs.
Moreover, we think that the loss of recruitment of SHP-2 activity to Y729 also
plays a major role in the sustained STAT5 activation by G-CSF-R-d715. It was
shown for a number of cytokine receptors, e.g., the leptin receptor and the shared
cytokine receptor subunit gp130, that SOCS3 and SHP-2 dock to the same
phosphotyrosine-based motif (57-60, 90, 91). Our data on the G-CSF-R (Figure
6) corroborate this and implicate Y729 as a common recruitment site for SOCS3
and SHP-2. Because SHP-2 was recently identified as a STAT5 phosphatase, a
model can be envisaged in which impaired recruitment of SHP-2 is key to the
loss of negative control of STAT5 activation (86, 87). In this scenario, reduced
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recruitment of SHP-2 activity to the G-CSF-R would thus result in increased
levels of active STAT5 complexes. Indeed, as shown in Figure 6B, G-CSF-R-
Y729 is essential for formation of a SHP-2-STAT5 complex which strongly
argues for a scenario in which loss of Y729 not only affects SOCS3-mediated
inhibition of STAT5 activity but also disrupts formation of a SHP-2-STAT5
complex that has been reported to contribute to STAT5 dephosphorylation.
In conclusion, our study has unveiled a new mechanism by which C-terminal
truncation mutants of G-CSF-R, associated with leukemic progression of SCN,
attain altered signaling abilities. While originally being attributed mainly to their
defective internalization properties (27, 31, 85), the loss of negative feedback
projected by SOCS3 and possibly SHP-2 via binding to Y729 of G-CSF-R, have
now been identified as additional signaling defects of truncated G-CSF-R. Our
results fit into a model in which the combined loss of regulation by SOCS3 and
SHP-2 contributes to the perturbed signaling by G-CSF-R-d715 resulting in an
increased STAT5/STAT3 activation ratio. 
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5.1 G-CSF signaling
Elucidation of the signaling pathways that are activated by G-CSF is important
for understanding regulation of normal granulopoiesis and will also shed light on
regulatory defects that underlie diseases characterized by disturbed
granulopoiesis, such as severe congenital neutropenia (SCN) and acute myeloid
leukemia (AML). As introduced in Chapter 1 of this thesis, major signaling
mechanisms activated by G-CSF, such as recruitment of STAT3 and
intermediates of the Ras pathway, depend on recruitment via one or more of the
four conserved tyrosines in the intracellular domain of the G-CSF-R. In this
thesis, the role of receptor tyrosine-mediated signaling mechanisms in
controlling G-CSF responses was further addressed. In Chapter 2, the individual
contribution of the G-CSF-R tyrosines in primary myeloid progenitors was
examined by transducing G-CSF-R knockout bone marrow cells with a G-CSF-
R tyrosine null mutant and single tyrosine add-back mutants. These studies
established that Y764 mediated strong proliferative and self-renewal signals in
colony assays and suspension cultures, which could be linked to activation of the
ERK pathway. In contrast, Y729 projected major inhibitory effects on G-CSF-
induced colony formation and maintenance of myeloid progenitor cells in
suspension culture, which was found to be associated with recruitment of the
suppressor of cytokine signaling SOCS3. In experiments described in Chapter 3,
the effects of different SOCS proteins on G-CSF signaling were investigated in
further detail, while in Chapter 4 the consequences of C-terminal truncations of
the G-CSF-R found in patients with SCN/AML on the suppressive action of
SOCS3 are reported. These studies have left a number of issues that require
further investigation, some of which will be discussed in this chapter. 
Although SOCS1 and SOCS3 are prominent inhibitors of Jak/STAT signaling, they
may also affect other pathways. For instance, SOCS1 inhibits c-kit and the FLT3
receptor, and has been shown to associate with the tyrosine kinases Tec, Pyk2 and FGF
receptor, the docking molecule GRB2, and the hematopoietic signaling protein Vav (1-
4). SOCS3 has been shown to bind to the Src-like tyrosine kinase Lck, FGF receptor
and Pyk2 (4). More recently Cacalano et al. reported that SOCS3 contributes to
degradation of the negative regulator of Ras signaling RasGap, thereby enhancing
ERK activation in response to cytokines and growth factors (5). How these
alternative mechanisms affect G-CSF responses of myeloid progenitor cells is
unknown.
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5.2 SHP-2 versus SOCS3 mediated inhibition via G-CSF-R-Y729
The fact that G-CSF-R-Y729 is an important recruitment site for both SOCS3
and SHP-2 (Chapters 2 and 4), is not unique for the G-CSF-R. For instance the
leptin receptor and gp130, the signal transducing subunit of oncostatin M (OSM),
leukemia inhibitory factor (LIF), IL-6 and IL-11 receptors have combined
docking sites for SOCS3 and SHP-2 (6-9). A mouse strain with gp130 lacking the
critical residue for SOCS3 and SHP-2 binding (Y757 or 759) resulted in arthritis-
like joint disease, with hyperresponsive T-cells and autoantibody production
(10). Although this model demonstrated that the combined recruitment site for
SHP-2 and SOCS3 is crucial for balanced signaling, the individual roles of SHP-
2 and SOCS3 remained unclear (10).
A number of studies have addressed the roles of negative feedback by SOCS3
and SHP-2 in gp130 and leptin signaling. Both SHP-2 and SOCS3 inhibit gp130
signaling in response to LIF and IL-6 (11, 12). In contrast, OSM signaling is
inhibited via Y759 of gp130, even in the absence of SOCS3 and SHP-2,
implicating involvement of another yet unknown inhibitor acting either directly
or indirectly via this tyrosine (13). Others used HEK 293 cells transfected with
SOCS3 or SHP-2, and mice expressing truncated gp130 that retained Y759 but
had severely reduced SOCS3 expression, to demonstrate that SOCS3 but not
SHP-2 inhibited leptin and gp130 signaling (7, 14, 15). Fairlie et al. addressed
this issue by generation of a gp130 mutant that recruited SHP-2 but not SOCS3
by changing the amino acid context around Y757. This receptor showed
enhanced responses to cytokine stimulation, indicating that recruitment of SHP-
2 is not involved in downregulation of gp130 signaling (16). More recently,
Fischer et al. also suggested that SOCS3 mediates desensitization of gp130
signaling in HEPG2 cells. They postulated that SOCS3 has to be induced first
and subsequently inhibits IL-6 signaling at a later stage (17). 
A direct comparison of the data from these different models with those reported
in this thesis on the G-CSF-R is complicated for two reasons. First, Y759 of
gp130 is also involved in the activation of the ERK route via SHP-2 (18) whereas
such a role for Y729 of the G-CSF-R could not be demonstrated (19). Second,
most of the cytokines that were tested in these reports do not activate STAT5, and
therefore a possible role of SHP-2 as a STAT5 phosphatase could not be tested in
these models. Future studies, in which e.g., siRNA-mediated knockdown
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technology is used, should give a better insight in the individual and combined
contribution of SOCS3 and SHP-2 in G-CSF-controlled granulopoiesis.
5.3 Contribution of SOCS1 to lineage choice?
In the experiments described in Chapter 3, it was shown that introduction of
SOCS1 or SOCS3 in primary bone marrow cells drastically inhibits G-CSF-
induced colony formation, establishing their role as suppressors of proliferation
in myeloid progenitor cells. This was recently confirmed by others, who
generated mice that lack SOCS3 in their hematopoietic cells. These animals
demonstrated increased size of G-CSF-dependent colonies and developed
neutrophilia or even inflammatory neutrophil infiltration into multiple tissues,
illustrating the importance of SOCS3 in controlling G-CSF-induced
granulopoiesis (20, 21). In addition we noted that introduction of SOCS1 resulted
in a partial shift in the composition of the G-CSF-colonies towards the
monocytic/macrophage-lineage. This applied particularly to SOCS1 and was not
observed for SOCS3 (Figure 1, A and B). These findings might suggest that
expression of SOCS1 in myeloid progenitors at a certain level favors macrophage
development at the expense of differentiation towards neutrophils in response to
G-CSF. Interestingly, two studies, of which one was performed with primary
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A
Figure 1: Introduction of SOCS1 stimulates macrophage-like differentiation of bone
marrow cells grown on G-CSF, depending on the presence of the SOCS box. A)
Differential counts of May Grünwald-Giemsa stained cells harvested from colony cultures
of primary bone marrow cells transduced with pBabe constructs with EGFP (control),
SOCS1, SOCS1dbox, SOCS3 or SOCS3dbox. Data are the mean of at least two
independent experiments.
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bone marrow as well, have shown that increased G-CSF-induced differentiation
into the macrophage lineage in myeloid cells is also observed when cells express
a G-CSF-R mutant in which Y729 is mutated (Y729F) (22, 23). Because this
mutant remains sensitive for inhibition by SOCS1 (Figure 2), but lacks
sensitivity to SOCS3 and SHP-2, SOCS1 is the most prominent negative
feedback mechanism that is still intact in these cells. Possibly, feedback mediated
by SOCS1, when not accompanied by signals of SOCS3 or SHP-2, facilitates a
differentiation shift from neutrophilic towards macrophage-like differentiation.
This hypothesis is corroborated by recent observations in mice lacking SOCS3 in
their hematopoietic progenitors. These animals demonstrated an increase in the
number and proportion of macrophages in G-CSF-induced colonies (21). Taken
together this suggests that SOCS proteins are not merely suppressors of
signaling, but also contribute to the control of lineage choices during
hematopoietic development. Recently, similar roles for SOCS-mediated negative
feedback in balancing T-cell differentiation (24, 25) and balancing IL-6 signaling
as pro- or anti-inflammatory response have been proposed (26-28).
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Figure 1: Introduction of SOCS1 stimulates macrophage-like differentiation of bone
marrow cells grown on G-CSF, depending on the presence of the SOCS box. B)
Photomicrographs of May Grünwald-Giemsa stained cells harvested from colony cultures
of primary bone marrow cells transduced with pBabe constructs with EGFP (control),
SOCS1 or SOCS1dbox. Magnification: 1000x.
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5.4 Differential effects of SOCS inhibition on G-CSF-induced STAT
activation revealed by mutation of critical domains in  the G-CSF receptor 
A surprising finding that emerged from the work presented in this thesis is that
the mechanisms by which SOCS1 and SOCS3 suppress G-CSF-induced
activation of different STAT proteins are markedly distinct. This became evident
by studying the effects of SOCS1 and SOCS3 on a panel of G-CSF-R mutants.
The first prominent difference is seen when WT G-CSF-R and mutant G-CSF-R-
d715 are compared. Whereas the inhibitory effects of SOCS1 and SOCS3 on
activation of STAT3 by G-CSF-R-d715 are preserved, inhibition of both SOCS
proteins on activation of STAT5 by G-CSF-R-d715 is completely lost (Figure 2).
This clearly indicates that, in contrast to inhibition of STAT3, SOCS-induced
inhibition of STAT5 requires additional mechanisms controlled by the G-CSF-R
C-terminus. Comparison of the action of SOCS1 and SOCS3 on more subtle G-
CSF-R mutants provided some leads about the possible nature of these
mechanisms. Data of these experiments are summarized in Figure 2. 
STAT5 activation by G-CSF-R-d715 is resistant to inhibition by both SOCS1
and SOCS3. This result was expected for SOCS3, which requires recruitment
to Y729 of G-CSF-R, but not for SOCS1. SOCS1 directly interacts with JAK
kinases, which bind to the membrane proximal region of G-CSF-R, and
therefore does not involve recruitment to G-CSF-R tyrosines (4, 29, 30).
Indeed, this is corroborated by the observation that STAT5 activation by the
G-CSF-R Null mutant is fully sensitive to inhibition by SOCS1. Strikingly,
Y729 becomes crucial for the effects of SOCS1 on STAT5 activation in G-
CSF-R deletion mutant d735 (Figure 2). Thus even though Y729 is
dispensable for SOCS1 function in the context of the full length G-CSF-R, its
presence is essential for inhibition of STAT5 activity of truncated G-CSF-
receptors. Although the reason for this differential requirement of Y729 for
inhibition of STAT5 by SOCS1 is currently unknown, these results imply that
SOCS1 itself is not able to abrogate STAT5 signaling by G-CSF-R-d735
unless combined with another mechanism mediated via Y729 or the G-CSF-
R C-terminus. As discussed in chapter 4, STAT5 dephosphorylation by SHP-
2 (which is recruited to Y729) is a candidate mechanism that could explain
the requirement of Y729 in the truncated receptors. The finding that Y729 is
not critical for SOCS1 effects on the Null mutant could imply that the G-
CSF-R C-terminus is also able to recruit SHP-2. Indeed, we were able to
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show that mutant d715-735, which lacks Y729 but retains the receptor C-
terminus, can still bind a significant amount of SHP-2 (Chapter 4).
5.5 G-CSF receptor internalization and SOCS-mediated inhibition
Previous studies have demonstrated that G-CSF-R-d715 is severely hampered in
both steady state and ligand-induced receptor internalization (31, 33). As repor-
ted in Chapter 4, lack of G-CSF-R-d715 internalization contributes to resistance
to SOCS3, although this effect is seen only when Y729 is lacking. We therefore
considered the possibility that defective internalization combined with the loss of
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Figure 2: Schematic representation of the intracellular domain of G-CSF mutants
and their sensitivity to SOCS1- and SOCS3-mediated inhibition of STAT3 and STAT5
signaling. Boxes 1 and 2 represent sub-domains conserved in the hematopoietin
superfamily. The white region in G-CSF-R-d749-769 and -d749-769F represents the
deleted receptor internalization region. - = No inhibition; +++ = maximal inhibition; ND =
not determined.
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Y729, contributed to loss of SOCS1-mediated inhibition of STAT5 activation by
G-CSF-R-d715. To address this question, we tested the effects of SOCS1 on G-
CSF-R-d749-769, which retains Y729 and most of the receptor C-terminus, but
is equally hampered in its internalization as G-CSF-R-d715 (30). We found that
SOCS1 still completely inhibits STAT5 activation by the G-CSF-R-d749-769 and
that loss of Y729 (G-CSF-R d749-769F) in combination with defective
internalization only marginally reduces inhibition by SOCS1 (Figure 2). This
supports the notion that reduced receptor internalization does not contribute to
the lack of sensitivity of G-CSF-R-d715 for SOCS1. 
The experiments described in this thesis have thus identified Y729 as being
important for the actions of SOCS1, and SOCS3, and also SHP-2, on G-CSF
responses. Because a major part of the data was obtained in a non-hematopoietic
cell model (HEK293), it is relevant to ask whether these conclusions hold for
myeloid cells. To this end, studies in the myeloid 32D cell system to address the
role of Y729 in downregulation of STAT3 and STAT5 signaling have been
performed in our lab. Electrophoretic mobility shift assays demonstrated that
inhibition of STAT3 activation was marginally affected by the lack of Y729,
whereas downregulation of STAT5 signaling was significantly alleviated by
mutation of Y729 (Aarts et al., manuscript in preparation). These experiments
confirm the data described in this thesis and argue for a major role for Y729 in
the downregulation of G-CSF-induced STAT5 activity also in a myeloid cell
context.
5.6 Current model of aberrant signaling of G-CSF-R-d715
The results presented in this thesis have shed further light on aberrant signaling
by truncated G-CSF-R found in SCN/AML patients (G-CSF-R-d715). In
addition to the previously reported defects in internalization, altered intracellular
distribution (31, 32, 33), and the loss of STAT3 recruitment sites (Y744 and C-
terminus)(22, 34) it is clear that altered negative feedback by SOCS1, SOCS3,
and SHP-2 also plays a major role in the aberrant signaling properties of G-CSF-
R-d715. This rather complex model will be explained step-by-step in Figure 3.
Since SOCS1 expression is not induced during G-CSF-induced neutrophilic
differentiation, only the roles of SHP-2 and SOCS3 are presented in the model.
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Figure 3 A: Reduced SOCS3 expression in G-CSF-R-d715 cells. Since
SOCS3 is a STAT3 target gene (35), the reduced STAT3 activation of G-CSF-R-
d715 contributes to the reduced expression of SOCS3 in G-CSF-R-d715 cells
(Chapter 4). 
Figure 3 B: SOCS3 inhibits STAT3 but not STAT5 activation by G-CSF-R-
d715. SOCS3 inhibits STAT3 and STAT5 activation by the WT G-CSF-R,
depicted in light grey in the left panel. STAT3 activation by the G-CSF-R-d715
is still sensitive to inhibition by SOCS3. It is conceivable, based on the SOCS3
titration experiments in luciferase assays, that even at low SOCS3 levels,
inhibition of STAT3 activation remains largely intact (shown in light grey). This
suggests that SOCS3, in the absence of Y729, is able to interact with JAK and
thus inhibits STAT3 activation. In contrast, STAT5 activation by G-CSF-R-d715
is completely resistant for negative feedback by SOCS3. 
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Figure 3 C: Loss of SHP-2 recruitment contributes to increased STAT5
activity by G-CSF-R-d715. Recruitment of SHP-2 is drastically impaired in the
absence of Y729 and the G-CSF-R C-terminus. Because SHP-2 has been
demonstrated to dephosphorylate STAT5, this will further contribute to loss of
inhibition of STAT5 activation.
Via the mechanisms shown in Figure 3, STAT3 activation by G-CSF-R-d715 is
inhibited whereas STAT5 activation is not. This results in increased levels of
activated STAT5. Since STAT3 is implicated in mediating cell cycle arrest (36)
whereas STAT5 acts a positive regulator of G-CSF-induced cell proliferation and
survival (37), the increased STAT5/STAT3 activation ratio results in enhanced
proliferation and survival and reduced growth arrest, which interferes with
proper neutrophil differentiation. 
5.7 Concluding remarks 
While initially regarded as specific inhibitors for JAK-STAT signaling, it has
become clear that SOCS proteins are involved in different signal transduction
pathways as well, and that they may also act via cooperation with other signaling
intermediates. Since the SOCS proteins are potent inhibitors capable of
interfering with known critical players in different diseases, it is interesting to
speculate about possible therapeutic applications of these proteins. Given the
important roles of SOCS family members in signaling by a large number of
cytokines and growth factors, the potential use of SOCS-derived signaling
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inhibitors requires development of techniques that allow exact targeting of the
affected cell populations in patients.  In addition, achieving the right time kinetics
of the inhibition is likely to be crucial in mediating appropriate negative feedback
as well. Interestingly, Shouda et al., were able to show proof of principle (38).
They demonstrated that injection of an adenoviral construct encoding SOCS3
into the joints of mice suffering from antigen-induced arthritis drastically
reduced the severity of the arthritis compared to mice injected with control
adenovirus. Although these results look promising, successful application of
SOCS-derived inhibitors in myeloid progenitors expressing truncated G-CSF
receptors will be considerable more complicated. However, the identification of
lack of SOCS- and SHP-2-mediated negative feedback in G-CSF-R-d715
signaling is important for future studies aimed at correcting the aberrant
granulopoiesis caused by loss of the G-CSF-R C-terminus.
General discussion
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Summary
Summary
G-CSF is the most important growth factor involved in the production of
neutrophilic granulocytes. Signaling routes activated upon ligand binding to the
G-CSF receptor (G-CSF-R) control survival, proliferation and differentiation of
myeloid progenitor cells towards mature neutrophils. Elucidation of the signaling
pathways involved in this process is important for understanding normal
neutrophil development and for better insights in diseases with perturbed
neutrophil production such as neutropenia and myeloid leukemia.
In Chapter 1 of this thesis an overview of the current knowledge on the G-CSF-R
is given and the signaling pathways activated by G-CSF are introduced. Upon G-
CSF binding, kinases of the JAK and Src kinase families become active and the
four tyrosines of the receptor, located at positions 704, 729, 744 and 764 are
phosphorylated. Multiple signaling pathways are subsequently activated via
recruitment of intermediates to these phosphorylated tyrosines as well as via
tyrosine independent mechanisms. A well known signaling route activated by the
G-CSF-R is the JAK-STAT pathway. The most prominent STATs that are
activated by G-CSF are STAT3, implicated in mediating a cell cycle arrest, and
STAT5, which contributes to proliferation and cell survival. 
Chapter 2 focuses on the role of the tyrosines residues of the G-CSF-R in primary
cells. Bone marrow cells of G-CSF-R knockout mice were transduced with G-
CSF-R-constructs: WT, mutant Null (that lacks all four tyrosines), or single
tyrosine add-back mutants (that each retain one tyrosine residue). Colony assays
of transduced cells showed that G-CSF-R tyrosines are dispensable for
proliferation of myeloid progenitor cells but are required for maintenance of
clonogenic capacity following repetitive replatings. In addition, the presence of
only Y764 strongly increased colony formation, proliferation and self-renewal
capacity of the cells. Inhibition of the ERK-MAPkinase pathway in these cells
blocked proliferation suggesting that ERK activity mediated via Y764 is
important for G-CSF-induced proliferation of primary cells. In contrast, the
presence of only tyrosine 704, 729 or 744 reduced colony growth. Tyrosine 729
was identified as the single G-CSF-R tyrosine residue involved in recruitment of
SOCS3, a member of the negative regulatory SOCS protein family. SOCS3 is
capable of downregulating G-CSF-induced STAT5 activity. Taken together these
observations indicate that G-CSF-R tyrosines, although dispensable for G-CSF-
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induced colony formation, activate additional signaling pathways that regulate
maintenance and outgrowth of myeloid progenitor cells.
In Chapter 3 the role of SOCS-mediated negative feedback on G-CSF-signaling
is examined in further detail. SOCS1 and SOCS3, but not CIS and SOCS2 were
capable of inhibiting G-CSF-induced STAT3 and STAT5 activation. During G-
CSF-induced differentiation of myeloid 32D cells, SOCS3 mRNA levels are
upregulated whereas SOCS1 expression remains comparable to levels in
proliferating cells. This indicates that SOCS3 is the most important SOCS
protein responsible for negative feedback during G-CSF-induced neutrophil
development. SOCS proteins contain multiple conserved domains that enable
them to inhibit signaling via different mechanisms such as inhibition of JAK
kinase activity or targeting of proteins for proteasomal degradation. We
demonstrated that presence of the SOCS box of SOCS1 and SOCS3 is required
for SOCS protein stabilization and for efficient inhibition of STAT signaling and
colony formation in response to G-CSF. These experiments suggest that
proteasomal degradation, mediated via the SOCS box is more important for
downregulation of STAT5 signaling than for downregulation of STAT3 signaling. 
Approximately 20% of severe congenital neutropenia (SCN) patients express
truncated G-CSF-receptors, such as G-CSF-R-d715, that lack a significant part of
the C-terminus. These receptors show multiple aberrations in G-CSF-induced
signaling including lack of receptor internalization and an increased
STAT5/STAT3 activation ratio.  Mice expressing the truncated G-CSF-R-d715
are neutropenic and hyperreactive to G-CSF-treatment, which results in
neutrophilia. In Chapter 4 we addressed whether lack of negative feedback by
SOCS proteins contributes to the phenotype of G-CSF-R-d715 mice. The
expression of SOCS3 mRNA is significantly reduced in cells expressing G-CSF-
R-d715. This is probably, at least in part, due to the reduced activation of STAT3
by G-CSF-R-d715. STAT5 activation by G-CSF-R-d715 is insensitive for
inhibition by SOCS3, which is likely due to the loss of the SOCS3 recruitment
site Y729 in the receptor C-terminus. In contrast, inhibition of STAT3 activation
by SOCS3 remains almost completely intact upon loss of the G-CSF-R C-
terminus. In addition, we demonstrated that G-CSF-R Y729 is not only a SOCS3
recruitment site but is also important for recruitment of the phosphatase SHP-2
to the G-CSF-R and for the formation of a complex between SHP-2 and STAT5.
Truncation of the G-CSF-R at aa 715 therefore disrupts recruitment of both
118
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SOCS3 and SHP-2. Since SHP-2 can act as a STAT5 phosphatase, it is
conceivable that loss of SHP-2 recruitment contributes to increased activation of
STAT5 of G-CSF-R-d715 as well. These results give an explanation for the
increased STAT5/STAT3 activation ratio of G-CSF-R-d715, which is implicated
in increased survival and proliferation and decreased differentiation of this SCN-
derived G-CSF-R mutant.
In chapter 5 the findings of this thesis are discussed in a broader perspective.
Additional data are provided that suggest a possible role for SOCS-mediated
feedback in directing lineage choice between neutrophilic and macrophage
differentiation. In addition, a model is introduced that explains how loss of SHP-
2 and SOCS3-mediated negative feedback contributes to the phenotype of the G-
CSF-R-d715 mouse. 
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Samenvatting
G-CSF is de belangrijkste groeifactor betrokken bij de aanmaak van neutrofiele
granulocyten. Signaalroutes die geactiveerd worden na binding van G-CSF aan
de G-CSF receptor (G-CSF-R) controleren overleving, celdeling en uitrijping
van myeloide voorloper cellen tot rijpe neutrofielen. Het in kaart brengen van de
signaal-transductieroutes die betrokken zijn bij deze processen is belangrijk voor
een goed begrip van de normale ontwikkeling van neutrofielen. Dit is ook van
belang voor het verkrijgen van een beter inzicht in ziektes met afwijkingen in de
aanmaak van neutrofielen zoals neutropenie en myeloide leukemie.
In hoofdstuk 1 van dit proefschrift wordt een overzicht gegeven van de huidige
kennis over de G-CSF-R en worden de signaalroutes die geactiveerd worden
door G-CSF geïntroduceerd. Na binding van G-CSF aan de receptor worden
JAK- en Src kinases geactiveerd en de 4 tyrosines, op posities 704, 729, 744 en
764 gefosforyleerd. Diverse signaal-transductieroutes worden geactiveerd, zowel
via recrutering aan de gefosforyleerde tyrosines, als via tyrosine-onafhankelijke
mechanismen. Een van de best bestudeerde signaalroutes van de G-CSF-R is
JAK-STAT activatie waarbij STAT3 en STAT5 het meest prominent geactiveerd
worden. STAT3 activatie draagt bij aan het tot stand komen van een celcyclus-
arrest dat vooraf gaat aan terminale neutrofiele uitrijping van myeloide cellen.
Activatie van STAT5 is daarentegen betrokken bij overleving en proliferatie van
myeloide cellen.
In studies beschreven in hoofdstuk 2 werd de rol van de tyrosines van de G-CSF-
R bestudeerd in primaire cellen. Beenmergcellen van G-CSF-R knockout muizen
werden getransduceerd met G-CSF-R constructen: WT, mutant Null (alle 4 de
tyrosines ontbreken) of mutanten die ieder nog slechts 1 tyrosine hebben.
Koloniekweken van getransduceerde cellen lieten zien dat de tyrosines niet
nodig zijn voor de proliferatie van myeloide voorlopercellen, maar dat tyrosines
wel vereist zijn voor het behouden van de capaciteit tot kolonievorming bij
herhaald her-uitplaten van de cellen. Aanwezigheid van alleen Y764 gaf een
sterke toename van kolonieaantallen, -groei en het vermogen tot zelf-
vermeerdering van de cellen. Het remmen van de ERK MAP kinase route in deze
cellen blokkeerde de proliferatie. Dit duidt erop dat ERK-activatie via Y764 een
belangrijke rol speelt bij de groei van primaire cellen. Aanwezigheid van alleen
tyrosine 704, 729 of 744 daarentegen verminderde het aantal G-CSF-
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geïnduceerde kolonies. Tyrosine 729 blijkt de enige bindingsplaats te zijn voor
SOCS3, een eiwit uit de suppressor of cytokine signaling (SOCS) familie, die
betrokken is bij negatieve terugkoppeling van signaal-transductie van cytokine
receptoren. SOCS3 remt de activatie van STAT5 door G-CSF. 
In hoofdstuk 3 wordt de remmende werking van SOCS eiwitten op de G-CSF-R
verder beschreven. SOCS1 en SOCS3 remden de activatie van STAT3 en STAT5
door G-CSF; CIS en SOCS2 hadden geen remmende werking. Tijdens G-CSF-
geïnduceerde differentiatie van myeloide 32D cellen ging de expressie van
SOCS3 mRNA omhoog terwijl de mRNA niveaus van SOCS1 vergelijkbaar
waren met cellen die bleven prolifereren. Dit wijst erop dat SOCS3  het
belangrijkste SOCS eiwit is dat verantwoordelijk is voor negatieve feedback
tijdens G-CSF-geïnduceerde differentiatie van neutrofielen. SOCS eiwitten
hebben meerdere geconserveerde domeinen die ze gebruiken om op
verschillende manieren signaling te remmen. Dit kan onder andere door het
induceren van proteasomale afbraak van eiwitten wat gemedieerd wordt door de
C-terminale, geconserveerde, SOCS box. In dit hoofdstuk is aangetoond dat de
SOCS boxen van SOCS1 en SOCS3 nodig zijn voor de stabilisatie van deze
SOCS eiwitten en voor een efficiënte remming van G-CSF-geinduceerde STAT-
activatie en kolonievorming. Deze experimenten impliceren verder dat regulatie
van proteasomale afbraak via de SOCS box een grotere rol speelt bij remming
van activatie van STAT5, dan van STAT3.
Ongeveer 20% van patienten die lijden aan ernstige aangeboren neutropenie
brengen getrunceerde G-CSF-receptoren, zoals G-CSF-R-d715, tot expressie.
Deze receptoren missen een deel van de C-terminus en vertonen afwijkingen in
hun signaal-transductie. Muizen die G-CSF-R-d715 tot expressie brengen lijden
aan neutropenie en zijn overgevoelig voor G-CSF stimulatie, wat resulteert in
neutrofilie. In hoofdstuk 4 hebben we onderzocht of het ontbreken van negatieve
feedback door SOCS eiwitten bijdraagt aan het fenotype van de G-CSF-R-d715
muis. De expressie van SOCS3 mRNA was significant lager in G-CSF-R-d715
cellen. Dit komt mogelijk, in ieder geval deels, door de verminderde STAT3-
activatie van G-CSF-R-d715. Activatie van STAT5 door G-CSF-R-d715 werd
niet geremd door SOCS3, wat zeer waarschijnlijk komt door het ontbreken van
Y729 in de G-CSF-R-d715. Remming van STAT3-activatie daarentegen bleef
vrijwel intact in afwezigheid van de G-CSF-R C-terminus. In dit hoofdstuk wordt
aangetoond dat Y729 niet alleen een bindingsplaats was voor SOCS3, maar ook
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voor het fosfatase SHP-2. Truncatie van de G-CSF-R bij aminozuur 715
verstoorde zowel de recrutering van SOCS3 als van SHP-2. Omdat SHP-2
STAT5 kan defosforyleren, kan het verlies van SHP-2-binding ook bijdragen aan
de toegenomen STAT5-activiteit van G-CSF-R-d715. Deze resultaten kunnen de
toegenomen ration van STAT5/STAT3-activatie van de G-CSF-R-d715
verklaren, die betrokken is bij verhoogde overleving en proliferatie van cellen die
G-CSF-R-d715 tot expressie brengen.
In hoofdstuk 5 worden de gegevens uit de experimenten in een breder kader
bediscussieerd. Verder worden aanvullende experimentele gegevens
gepresenteerd die wijzen naar een mogelijke rol voor SOCS-gemedieerde
negatieve feedback in het reguleren van de neutrofiele differentiatie versus
macrofaag-differentiatie. Tot slot wordt er een model gepresenteerd dat verklaart
hoe het ontbreken van negatieve feedback door SHP-2 en SOCS3 bijdraagt aan
het fenotype van het G-CSF-R-d715 muismodel.
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Abbreviations
7-AAD 7-amino actinomycin D
aa amino acid
AML acute myeloid leukemia
BC C-terminal barrel
BN N-terminal barrel
CFU-G colony-forming unit-granulocyte
CRH cytokine receptor homology
EGFR epidermal growth factor receptor
Epo erythropoietin
ESS extended SH2 subdomain
FCS fetal calf serum
FLT3 fms like tyrosine kinase 3
FKHR forkhead in rhabdomyosarcoma
FNIII fibronectin type III
G-CSF granulocyte colony-stimulating factor
G-CSF-R granulocyte colony-stimulating factor receptor
GH growth hormone
GM-CSF granulocyte-macrophage colony-stimulating factor
GRB2 growth factor receptor-binding protein 2
HCK hematopoietic cell kinase
Ig immunoglobulin
IL interleukin
IP immuno precipitation
JAK Janus kinase or just another kinase
KIR kinase inhibitory region
LIF leukemia inhibitory factor
MAP kinase mitogen-activated protein kinase
MDS myelodysplastic syndrome
OSM oncostatin M
PI-3K phosphatidylinositol 3-kinase
PKB protein kinase B
SCN severe congenital neutropenia
SH2 src homology region 2
SHC src homologous and collagen
SHIP SH2-containing inositol phosphatase
SHP SH2-domain containing tyrosine phosphatase
SOCS suppressor of cytokine signaling
STAT signal tranducer and activator of transcription
tg transgenic 
Tpo thrombopoietin
WB Western blotting
WT wild type
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